CN114657133A - Pluripotent stem cell for expressing shRNA and/or shRNA-miR of targeted IL-4R alpha - Google Patents
Pluripotent stem cell for expressing shRNA and/or shRNA-miR of targeted IL-4R alpha Download PDFInfo
- Publication number
- CN114657133A CN114657133A CN202011526223.3A CN202011526223A CN114657133A CN 114657133 A CN114657133 A CN 114657133A CN 202011526223 A CN202011526223 A CN 202011526223A CN 114657133 A CN114657133 A CN 114657133A
- Authority
- CN
- China
- Prior art keywords
- shrna
- seq
- mir
- pluripotent stem
- hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004055 small Interfering RNA Substances 0.000 title claims abstract description 192
- 108091027967 Small hairpin RNA Proteins 0.000 title claims abstract description 189
- 210000001778 pluripotent stem cell Anatomy 0.000 title claims abstract description 139
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 title claims abstract description 92
- 230000014509 gene expression Effects 0.000 claims abstract description 164
- 210000004027 cell Anatomy 0.000 claims abstract description 149
- 210000001808 exosome Anatomy 0.000 claims abstract description 54
- 239000012636 effector Substances 0.000 claims abstract description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 135
- 102000039446 nucleic acids Human genes 0.000 claims description 98
- 108020004707 nucleic acids Proteins 0.000 claims description 98
- 150000007523 nucleic acids Chemical class 0.000 claims description 98
- 230000001939 inductive effect Effects 0.000 claims description 45
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims description 38
- 230000008685 targeting Effects 0.000 claims description 38
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 claims description 33
- 239000002679 microRNA Substances 0.000 claims description 33
- 230000028993 immune response Effects 0.000 claims description 32
- 238000012545 processing Methods 0.000 claims description 28
- 108700002010 MHC class II transactivator Proteins 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 25
- 108091070501 miRNA Proteins 0.000 claims description 24
- 102100026371 MHC class II transactivator Human genes 0.000 claims description 23
- 230000002441 reversible effect Effects 0.000 claims description 21
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 claims description 20
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 claims description 20
- 230000001064 anti-interferon Effects 0.000 claims description 20
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 19
- 201000008937 atopic dermatitis Diseases 0.000 claims description 19
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 18
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 16
- 238000013518 transcription Methods 0.000 claims description 16
- 230000035897 transcription Effects 0.000 claims description 16
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 15
- 230000000295 complement effect Effects 0.000 claims description 15
- 238000010362 genome editing Methods 0.000 claims description 15
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 14
- 230000001105 regulatory effect Effects 0.000 claims description 14
- 230000009368 gene silencing by RNA Effects 0.000 claims description 13
- 108020004999 messenger RNA Proteins 0.000 claims description 12
- 108700005078 Synthetic Genes Proteins 0.000 claims description 11
- 210000001519 tissue Anatomy 0.000 claims description 11
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 9
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 108700028369 Alleles Proteins 0.000 claims description 8
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 8
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 8
- 210000004504 adult stem cell Anatomy 0.000 claims description 8
- 239000000539 dimer Substances 0.000 claims description 8
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 8
- 101150076800 B2M gene Proteins 0.000 claims description 7
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 7
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 7
- 108010032038 Interferon Regulatory Factor-3 Proteins 0.000 claims description 7
- 108010032036 Interferon Regulatory Factor-7 Proteins 0.000 claims description 7
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 claims description 7
- 102100026965 RISC-loading complex subunit TARBP2 Human genes 0.000 claims description 7
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 6
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 claims description 6
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 claims description 6
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 claims description 6
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 claims description 6
- 102100040482 HLA class II histocompatibility antigen, DR beta 3 chain Human genes 0.000 claims description 6
- 102100028636 HLA class II histocompatibility antigen, DR beta 4 chain Human genes 0.000 claims description 6
- 102100028640 HLA class II histocompatibility antigen, DR beta 5 chain Human genes 0.000 claims description 6
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims description 6
- 108010093061 HLA-DPA1 antigen Proteins 0.000 claims description 6
- 108010086786 HLA-DQA1 antigen Proteins 0.000 claims description 6
- 108010065026 HLA-DQB1 antigen Proteins 0.000 claims description 6
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 claims description 6
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims description 6
- 108010061311 HLA-DRB3 Chains Proteins 0.000 claims description 6
- 108010040960 HLA-DRB4 Chains Proteins 0.000 claims description 6
- 108010016996 HLA-DRB5 Chains Proteins 0.000 claims description 6
- 101001125123 Homo sapiens Interferon-inducible double-stranded RNA-dependent protein kinase activator A Proteins 0.000 claims description 6
- 102100038070 Interferon regulatory factor 7 Human genes 0.000 claims description 6
- 102100029408 Interferon-inducible double-stranded RNA-dependent protein kinase activator A Human genes 0.000 claims description 6
- 108020001507 fusion proteins Proteins 0.000 claims description 6
- 210000001178 neural stem cell Anatomy 0.000 claims description 6
- -1 2-5As Proteins 0.000 claims description 5
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 5
- 101000974349 Homo sapiens Nuclear receptor coactivator 6 Proteins 0.000 claims description 5
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 108020004459 Small interfering RNA Proteins 0.000 claims description 5
- 230000006058 immune tolerance Effects 0.000 claims description 4
- 230000002452 interceptive effect Effects 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 101000880398 Homo sapiens Metalloreductase STEAP3 Proteins 0.000 claims description 3
- 108030000910 L-aspartate oxidases Proteins 0.000 claims description 3
- 102100037653 Metalloreductase STEAP3 Human genes 0.000 claims description 3
- 101150084233 ago2 gene Proteins 0.000 claims description 3
- 230000003266 anti-allergic effect Effects 0.000 claims description 3
- 230000001088 anti-asthma Effects 0.000 claims description 3
- 239000000924 antiasthmatic agent Substances 0.000 claims description 3
- 230000001276 controlling effect Effects 0.000 claims description 3
- 210000004602 germ cell Anatomy 0.000 claims description 3
- 210000001654 germ layer Anatomy 0.000 claims description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 3
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims description 2
- 102100031618 HLA class II histocompatibility antigen, DP beta 1 chain Human genes 0.000 claims description 2
- 108010045483 HLA-DPB1 antigen Proteins 0.000 claims description 2
- 108010024164 HLA-G Antigens Proteins 0.000 claims description 2
- 101000847058 Homo sapiens Exportin-5 Proteins 0.000 claims description 2
- 108091060552 Pasha (protein) Proteins 0.000 claims description 2
- 102000014450 RNA Polymerase III Human genes 0.000 claims description 2
- 108010078067 RNA Polymerase III Proteins 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 102000047351 Exportin-5 Human genes 0.000 claims 1
- 101000763328 Homo sapiens RISC-loading complex subunit TARBP2 Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 abstract description 31
- 201000010099 disease Diseases 0.000 abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 11
- 208000026935 allergic disease Diseases 0.000 abstract description 11
- 230000007815 allergy Effects 0.000 abstract description 11
- 230000005764 inhibitory process Effects 0.000 abstract description 10
- 108020004414 DNA Proteins 0.000 description 114
- 239000013612 plasmid Substances 0.000 description 91
- 108020005004 Guide RNA Proteins 0.000 description 71
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 31
- 239000013598 vector Substances 0.000 description 30
- 102000004388 Interleukin-4 Human genes 0.000 description 25
- 108090000978 Interleukin-4 Proteins 0.000 description 25
- 230000000694 effects Effects 0.000 description 23
- 229940028885 interleukin-4 Drugs 0.000 description 23
- 201000009961 allergic asthma Diseases 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 239000000411 inducer Substances 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 14
- 108091033409 CRISPR Proteins 0.000 description 13
- 108010082117 matrigel Proteins 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 238000003198 gene knock in Methods 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000004098 Tetracycline Substances 0.000 description 11
- 230000000735 allogeneic effect Effects 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 230000006698 induction Effects 0.000 description 11
- 229930101283 tetracycline Natural products 0.000 description 11
- 229960002180 tetracycline Drugs 0.000 description 11
- 235000019364 tetracycline Nutrition 0.000 description 11
- 150000003522 tetracyclines Chemical class 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 229960002930 sirolimus Drugs 0.000 description 10
- 238000012258 culturing Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000010276 construction Methods 0.000 description 7
- 238000007710 freezing Methods 0.000 description 7
- 230000008014 freezing Effects 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 208000024711 extrinsic asthma Diseases 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 6
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 101100144701 Mus musculus Drosha gene Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 210000002242 embryoid body Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 108091007428 primary miRNA Proteins 0.000 description 5
- 230000002459 sustained effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000244203 Caenorhabditis elegans Species 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 4
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 4
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 4
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 238000006471 dimerization reaction Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101000869796 Homo sapiens Microprocessor complex subunit DGCR8 Proteins 0.000 description 3
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 3
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 102100032459 Microprocessor complex subunit DGCR8 Human genes 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- 108700026220 vif Genes Proteins 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 2
- 102000007445 2',5'-Oligoadenylate Synthetase Human genes 0.000 description 2
- 108010086241 2',5'-Oligoadenylate Synthetase Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 2
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 2
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 2
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- BKPRVQDIOGQWTG-ICOOEGOYSA-N [(1s,2r)-2-phenylcyclopropyl]azanium;[(1r,2s)-2-phenylcyclopropyl]azanium;sulfate Chemical compound [O-]S([O-])(=O)=O.[NH3+][C@H]1C[C@@H]1C1=CC=CC=C1.[NH3+][C@@H]1C[C@H]1C1=CC=CC=C1 BKPRVQDIOGQWTG-ICOOEGOYSA-N 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000011129 allogeneic cell therapy Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012595 freezing medium Substances 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 102000055229 human IL4 Human genes 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000002487 multivesicular body Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 229940087824 parnate Drugs 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000754 repressing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 210000003014 totipotent stem cell Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- SGKRLCUYIXIAHR-NLJUDYQYSA-N (4r,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-NLJUDYQYSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- 101150072531 10 gene Proteins 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000001045 Connexin 43 Human genes 0.000 description 1
- 108010069241 Connexin 43 Proteins 0.000 description 1
- FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 102100032839 Exportin-5 Human genes 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 1
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 description 1
- 101000780643 Homo sapiens Protein argonaute-2 Proteins 0.000 description 1
- 102000043138 IRF family Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 description 1
- 101710112663 Interleukin-13 receptor subunit alpha-1 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 108020005198 Long Noncoding RNA Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 101100489688 Mus musculus Eif4enif1 gene Proteins 0.000 description 1
- 101100198353 Mus musculus Rnasel gene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100034207 Protein argonaute-2 Human genes 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108010009386 Type I Interleukin-4 Receptors Proteins 0.000 description 1
- 102000009509 Type I Interleukin-4 Receptors Human genes 0.000 description 1
- 108010002120 Type II Interleukin-4 Receptors Proteins 0.000 description 1
- 102000000535 Type II Interleukin-4 Receptors Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 101150038500 cas9 gene Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000001726 chromosome structure Anatomy 0.000 description 1
- 238000013373 clone screening Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 230000029036 donor selection Effects 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100001078 no known side-effect Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0611—Primordial germ cells, e.g. embryonic germ cells [EG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
The invention discloses a pluripotent stem cell for expressing shRNA and/or shRNA-miR of a target IL-4R alpha, wherein an expression sequence of shRNA and/or shRNA-miR of the target IL-4R alpha is introduced into a genome of the pluripotent stem cell or a derivative thereof. After the pluripotent stem cells or the derivatives thereof express shRNA and/or shRNA-miR of the target IL-4R alpha, the exosomes carry the effector RNA molecules to be combined with target cells and then release the target cells, so that the inhibition of the expression of the IL-4R alpha can be used for treating allergy, asthma and other related diseases.
Description
Technical Field
The invention belongs to the technical field of genetic engineering, and particularly relates to a pluripotent stem cell for expressing shRNA and/or shRNA-miR of a target IL-4R alpha.
Background
IL-4 was originally named B cell growth factor-1 because of its ability to promote B lymphocyte proliferation. Some laboratories are called B cell stimulating factor-1, T cell growth factor-2, etc. Later, the gene clone was successful and was named Interleukin 4 (IL-4). The chromosome of the gene of the human IL-4 is positioned at 5q31, and the mature human IL-4 consists of 129 amino acid residues and has the molecular mass of 18-19 kDa. IL-4 is produced predominantly by the Th2 subset of activated T cells, while other cells such as mast cells, eosinophils, etc. may also secrete small amounts of IL-4 and induce differentiation of naive CD4+ T cells to the Th2 subset. IL-4 and IL-13 play an important role in inflammation of bronchial asthma, and IL-13 and IL-4 play important roles in allergy, atopic dermatitis, etc., but they must bind to a receptor complex on a target cell to exert their biological activities. IL-4 receptors (IL-4 receptors, IL-4R) are divided into two subtypes, type I IL-4 receptors and type II IL-4 receptors. Type I IL-4R consists of an IL-4R α (IL-4 Receptor α) chain (CD124) and a γ c chain (CD 132); type II IL-4R consists of the IL-4R alpha chain (CD124) and the IL-13R alpha 1 chain (CD213 alpha 1), so IL-13 shares the type II IL-4R receptor, IL-4R alpha, with IL-4 for signaling. Therefore, IL-4R alpha becomes a new target for treating allergy, asthma and atopic dermatitis, and IL-4R alpha blocker (anti-IL-4R alpha antibody) can be used as a therapeutic drug for allergy and asthma. Currently, the clinical IL-4R α antibodies include Dupixent, the IL-4R α antibody CBP-201 from Suzhou Connectard. However, anti-IL-4R α antibodies have a short duration of action, require long-term injection, and are costly to patients.
Exosomes, designated "exosomes" by Johnstone in 1987. Nowadays, it refers in particular to discoidal vesicles with a diameter of 40-100 nm. Many cells secrete exosomes under both normal and pathological conditions. It is mainly from the multivesicular body formed by the invagination of intracellular lysosome particles, and is released into extracellular matrix after the fusion of the outer membrane of the multivesicular body and cell membrane. When secreted from a host cell into a recipient cell, exosomes may modulate the biological activity of the recipient cell by way of the proteins, nucleic acids, lipids, etc. they carry. Exosome-mediated intercellular communication is mainly through the following three modes: one is that exosome membrane proteins can bind to target cell membrane proteins, thereby activating signaling pathways within the target cell. Secondly, in the extracellular matrix, the exosome membrane protein can be cut by protease, and the cut fragment can be used as a ligand to be combined with a receptor on a cell membrane, so that a signal path in the cell is activated. It has been reported that some proteins on the membrane of exosomes are not detectable on the cell membrane from which they were derived. And thirdly, the exosome membrane can be directly fused with a target cell membrane, and the contained protein, mRNA and microRNA are released non-selectively. At present, research on gene therapy, tumor therapy and the like by carrying siRNA, chemical small molecule drugs and the like by exosome has been tried.
Stem cells are "seed" cells with self-renewal ability and differentiation ability into specific functional somatic cells, have the potential to regenerate into various tissues, organs and human bodies, and play a central and irreplaceable role in immune response, aging, tumorigenesis and other important biological activities. Stem cells are mainly classified into: totipotent stem cells (Totipotent stem cells), Pluripotent Stem Cells (PSCs), and adult stem cells (adult stem cells). The typical PSCs mainly include Embryonic Stem Cells (ESCs), Embryonic Germ Cells (EGCs), Embryonic Carcinoma Cells (ECCs), Induced Pluripotent Stem Cells (iPSCs), and the like, and such cells have a very deep and wide application prospect due to their powerful functions and can be restricted to some extent by ethics.
Therefore, the development of the pluripotent stem cell or the derivative thereof which can express the shRNA and/or shRNA-miR of the target IL-4R alpha and the exosome secreting the shRNA and/or shRNA-miR of the target IL-4R alpha in the human body is of great significance.
However, the conception or establishment of the autologous iPSCs cell bank or the immune matched PSCs cell bank requires great expenditure of money, material resources and manpower. The molecular immunological basis for allogeneic recipient organ, tissue or cell transplantation is based primarily on the matching of the classical major histocompatibility complexes MHC-I and MHC-II (human HLA-I, HLA-II). By 6 months 2019, over 20000 HLA system alleles have been identified and named, and only 5000 allele factors of classical HLA-A, B, C are respectively exceeded, and various possible random combinations of these classical HLA-I/II alleles will be astronomical numbers, and as the number of combinations found for new alleles increases, there is a great obstacle to tissue matching and donor selection before organ, tissue and cell transplantation, and also great difficulty in constructing a PSCs cell library covering the immune match of the human population.
Thus, the construction of allogeneic immune-compatible, universal PSCs is imminent. In recent years, a plurality of reports have been provided that the deletion expression of genes on the cell surfaces of HLA-I and HLA-II or the genes thereof is realized by knocking out genes such as B2M, CIITA and the like, so that the cells have immune tolerance or escape T/B cell specific immune response, and universal PSCs with immune compatibility are generated, thereby laying an important foundation for the application of wider universal PSCs source cells, tissues and organs. Also, cells have been reported to overexpress CTLA4-Ig, PD-L1 and thereby inhibit allogeneic immune rejection. Recently, it has been reported that when B2M and CIITA are knocked out, CD47 is knocked in, so that cells obtain escape specific immune response, and have immune tolerance or escape natural immune response of cells such as NK cells, so that the cells have more comprehensive and stronger immune compatibility characteristics. However, these approaches are either not fully immune compatible, and still allow for immunological rejection of the allogens by other routes; or completely eliminate the allogeneic immune rejection response, but simultaneously make the cells of the donor-derived transplant lose the antigen presenting capability, which brings great risk of diseases such as tumorigenicity and virus infection to the recipient.
Therefore, it is also reported that, when the B2M is not directly knocked out, the HLA-A, HLA-B is knocked out or the CIITA is knocked out together, the HLA-C is kept, 12 HLA-C immune matching antigens covering more than 90% of people are constructed, so that the transplanted cells still have a certain degree of antigen presenting function, and the inherent immune response of NK cells can be inhibited through the HLA-C. However, in the cells, the antigen types presented by the HLA-I antigens are reduced by more than two thirds, the integrity of the presented antigens is reduced irreversibly greatly, the cells have great bias on the presentation of various tumor, virus and other disease antigens, the risks of diseases such as tumor and virus infection are still kept to a certain extent, and the pathogenic risk is higher under the condition of simultaneous CIITA knockout; secondly, 12 high-frequency immune match HLA-C antigen species are very different, and the part of the area can only account for 70 percent by verification and calculation, while the HLA data of large sample size which is not authoritative currently in China, Indian and other big countries is displayed, so that the prepared general PSCs are still subjected to huge match vacancy tests; thirdly, the method can go through repeated gene editing for a plurality of times, at least two rounds of single cell isolation culture meters are needed according to each gene editing, the whole process needs at least more than six rounds of single cell isolation culture, and the processes are inevitable and cause various unpredictable mutations of cells due to multiple times of gene editing off-target or unstable chromatin or due to passage proliferation of a large number of single cells, thereby further inducing various problems of carcinogenesis, metabolic diseases and the like. It follows that such immuno-compatible schemes are also a matter of convenience in the "transition period", and many problems remain that are not better solved.
In addition, inducing killing of the suicide gene after donor tissue and cell disease has been induced, which results in serious tissue necrosis, cytokine storm and other unpredictable disease risk problems, and it is a big problem that proper donor cells, tissues and organs do not exist after the cell death of the design.
Disclosure of Invention
The present invention aims to provide a pluripotent stem cell or a derivative thereof;
it is another object of the present invention to provide an exosome;
still another object of the present invention is to provide the use of said pluripotent stem cells or derivatives thereof and/or said exosomes for the preparation of an anti-allergic, atopic dermatitis and/or anti-asthma therapeutic drug.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
in a first aspect of the present invention, there is provided a pluripotent stem cell or a derivative thereof, wherein an expression sequence of shRNA and/or shRNA-miR targeting IL-4 ra is introduced into the genome of the pluripotent stem cell or the derivative thereof.
The research of the invention discovers that after an shRNA/shRNA-miR expression sequence of a targeted IL-4R alpha is introduced into a pluripotent stem cell or a derivative thereof, exosomes secreted in the pluripotent stem cell or the derivative thereof contain high-abundance shRNA/shRNA-miR of the targeted IL-4R alpha and mature siRNA, and the exosomes carry effect RNA molecules to be combined with the target cell and then released, so that the expression of the IL-4R alpha is inhibited, and the effect of treating allergy, atopic dermatitis, asthma and other related diseases is achieved.
The sequence of the shRNA and/or shRNA-miR of the target IL-4R alpha is shown in SEQ ID NO. 101-SEQ ID NO. 103.
In a second aspect of the invention, a pluripotent stem cell or a derivative thereof is provided, wherein an expression sequence of shRNA and/or shRNA-miR targeting IL-4R alpha is introduced into the genome of the pluripotent stem cell or the derivative thereof, and the B2M gene and/or CIITA gene of the genome of the pluripotent stem cell or the derivative thereof is knocked out.
When B2M and CIITA genes are knocked out, the influence of HLA-I and HLA-II molecules is completely eliminated, and therefore, the tumor treatment effect is optimal.
In a third aspect of the present invention, there is provided a pluripotent stem cell or a derivative thereof, wherein an expression sequence of shRNA and/or shRNA-miR targeting IL-4 ra is introduced into the genome of the pluripotent stem cell or the derivative thereof, and a first nucleic acid molecule is further introduced into the genome of the pluripotent stem cell or the derivative thereof;
and, a second nucleic acid molecule is introduced into the 3' UTR region of an immune response-associated gene in said pluripotent stem cell or a derivative thereof;
the first nucleic acid molecule encodes a small nucleic acid molecule that mediates RNA interference, which small nucleic acid molecule specifically targets the transcript of the second nucleic acid molecule, and which small nucleic acid molecule does not target any other mRNA or incrna of the pluripotent stem cell or a derivative thereof.
In the technical scheme, the small nucleic acid molecule coded by the first nucleic acid molecule can be specifically combined with a transcription product of a second nucleic acid molecule introduced from a 3' UTR region of an immune response related gene, so that an RNA interference program is started, mRNA of the immune response related gene is degraded or silenced, and the expression of the immune response related gene is blocked, so that the cell has the immune compatibility characteristic, and the allogeneic immune rejection response can be eliminated or reduced. Moreover, the RNA interference program only acts on such engineered pluripotent stem cells or derivatives thereof, and thus, when such cells or derivatives are transplanted into a recipient, RNA interference of the immune response-related gene mediated by the small nucleic acid molecule encoded by the first nucleic acid molecule and the second nucleic acid molecule introduced at the 3 'UTR of the immune response-related gene only acts on the donor cells, without interfering with the genome of the recipient's cells.
Further, the small nucleic acid molecule comprises short interfering nucleic acid, short interfering RNA and double-stranded RNA, preferably at least one of miRNA, shRNA and shRNA-miR.
Further, the pluripotent stem cell or the derivative thereof is derived from a human; the sequence of the small nucleic acid molecule is a random sequence of a non-human species that does not target any mRNA or incrna of a human.
The small nucleic acid molecule is preferably derived from caenorhabditis elegans. For example:
5’-TTGTACTACACAAAAGTACTG-3’(SEQ ID NO.1);
5’-TCACAACCTCCTAGAAAGAGTAGA-3’(SEQ ID NO.100)。
further, the second nucleic acid molecule comprises a reverse complement of at least 3 repeated small nucleic acid molecule sequences, preferably 6-10 repeated small nucleic acid molecule sequences.
Furthermore, an inducible gene expression system is introduced into the genome of the pluripotent stem cell or the derivative thereof for regulating the expression of the first nucleic acid molecule.
In the technical scheme, the inducible gene expression system is regulated and controlled by an exogenous inducer, and the opening and closing of the inducible gene expression system are controlled by adjusting the addition amount, the duration action time and the type of the exogenous inducer, so that the expression quantity of small nucleic acid molecules is controlled.
When the inducible gene expression system is started, the transcription product of the small nucleic acid molecule which is normally expressed and the second nucleic acid molecule which is introduced into the 3' UTR region of the immune response related gene is specifically combined, so that an RNA interference program is started, mRNA of the immune response related gene is degraded or silenced, and the expression of the immune response related gene is blocked. Thus, when such cells or derivatives are transplanted into a recipient, the allogeneic immune rejection response may be eliminated or reduced, and the immune compatibility between the transplant and the recipient may be improved.
When the graft suffers from pathological changes, the inducible gene expression system can be closed by adding an exogenous inducer, so that the expression of small nucleic acid molecules is closed, the interference effect of the small nucleic acid on mRNA of the immune response related gene is stopped, the normal expression of the immune response related gene is recovered, the antigen presenting capability of graft cells is recovered, and the receptor can remove the pathological graft, so that the clinical safety of the pluripotent stem cells or the derivatives thereof is improved, and the value of the pluripotent stem cells in clinical application is greatly expanded.
Moreover, the RNA interference program only acts on such engineered pluripotent stem cells or derivatives thereof, and thus, when such cells or derivatives are transplanted into a recipient, RNA interference of the immune response-associated gene mediated by the small nucleic acid molecule encoded by the first nucleic acid molecule and the second nucleic acid molecule introduced at the 3' UTR of the immune response-associated gene only acts on the donor cells, without interfering with the genome of the recipient cells.
In a fourth aspect of the present invention, there is provided:
the genome of the pluripotent stem cell or the derivative thereof is introduced with an expression sequence of shRNA and/or shRNA-miR of a target IL-4R alpha, and the genome of the pluripotent stem cell or the derivative thereof is also introduced with an expression sequence of at least one immune compatible molecule for regulating and controlling the expression of genes related to immune response in the pluripotent stem cell or the derivative thereof.
In the technical scheme, the immune compatible molecules can regulate and control the expression of genes related to immune response in the pluripotent stem cells or the derivatives thereof, so that the immunogenicity of the pluripotent stem cells or the derivatives thereof is low, and when the pluripotent stem cells or the derivatives thereof are transplanted into a recipient, the allogeneic immune rejection response can be eliminated or reduced, and the immune compatibility between the transplant and the recipient is improved. The transplant can endogenously and continuously express shRNA/shRNA-miR of the targeted IL-4R alpha at a receptor, and after the inhibition factors are wrapped by exosomes, the exosomes carry the inhibition factors to be combined with target cells and then release the target cells, so that the expression of the IL-4R alpha is inhibited, and the effect of treating allergy, atopic dermatitis, asthma and other related diseases is achieved.
Furthermore, an inducible gene expression system is also introduced into the genome of the pluripotent stem cell or the derivative thereof and is used for regulating and controlling the expression of the immune compatible molecules.
In the technical scheme, the inducible gene expression system is regulated by an exogenous inducer, the on and off of the inducible gene expression system are controlled by adjusting the addition amount, the duration action time and the type of the exogenous inducer, and the expression quantity of an immune compatible molecular expression sequence is further controlled, so that the reversible regulation of the immune compatibility of the pluripotent stem cells or derivatives thereof is realized. When the immune compatible molecule is normally expressed, the expression of genes related to immune response in the pluripotent stem cell or the derivative thereof is inhibited or overexpressed, so that when allogeneic cell therapy is performed, allogeneic immune rejection response can be eliminated or reduced, and the immune compatibility between the donor cell and the recipient can be improved. When the donor cell is diseased, the expression of the immune compatible molecules can be closed by induction of an exogenous inducer, so that the HLA class I molecules can be reversibly re-expressed on the surface of the donor cell, the antigen presenting capability of the donor cell is recovered, and then the receptor immune system enables the receptor to eliminate the diseased cell by identifying unmatched HLA class I molecules or by cross HLA class I molecule antigen presenting (antigen presenting/identifying between classical incompatible HLA) mutated molecules, so that the clinical safety of the general pluripotent stem cell or the derivative thereof is improved, and the value of the general pluripotent stem cell in clinical application is greatly expanded.
With respect to the third and fourth aspects of the present invention, further, the genes associated with immune response include:
(1) major histocompatibility complex genes including at least one of HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DQA1, HLA-DQB1, HLA-DPA1 and HLA-DPB 1;
(2) major histocompatibility complex-associated genes including at least one of B2M and CIITA.
With respect to the fourth aspect of the present invention, further, the immune-compatible molecule comprises at least one of:
(1) an immune tolerance-related gene including at least one of CD47 and HLA-G;
(2) HLA-C molecules, including HLA-C multiple alleles of which the proportion in the population is over 90 percent in total, or fusion protein genes consisting of the HLA-C multiple alleles of which the proportion is over 90 percent and B2M;
(3) shRNA and/or shRNA-miR targeting major histocompatibility complex genes including at least one of HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DQA1, HLA-DQB1, HLA-DPA1 and HLA-DPB 1;
(4) shRNA and/or shRNA-miR targeting major histocompatibility complex-associated genes including at least one of B2M and CIITA.
Furthermore, the target sequence of the shRNA and/or shRNA-miR targeting B2M is selected from one of SEQ ID NO. 8-SEQ ID NO. 10;
the target sequence of the shRNA and/or shRNA-miR of the targeting CIITA is selected from one of SEQ ID NO. 11-SEQ ID NO. 13;
the target sequence of the shRNA and/or shRNA-miR of the target HLA-A is selected from one of SEQ ID NO. 14-SEQ ID NO. 16;
the target sequence of the shRNA and/or shRNA-miR of the target HLA-B is selected from one of SEQ ID NO. 17-SEQ ID NO. 19;
the target sequence of the shRNA and/or shRNA-miR of the target HLA-C is selected from one of SEQ ID NO. 20-SEQ ID NO. 22;
the target sequence of the shRNA and/or shRNA-miR of the target HLA-DRA is selected from one of SEQ ID NO. 23-SEQ ID NO. 25;
the target sequence of the shRNA and/or shRNA-miR of the target HLA-DRB1 is selected from one of SEQ ID NO. 26-SEQ ID NO. 28;
the target sequence of the shRNA and/or shRNA-miR of the target HLA-DRB3 is selected from one of SEQ ID NO. 29-SEQ ID NO. 30;
the target sequence of the shRNA and/or shRNA-miR of the target HLA-DRB4 is selected from one of SEQ ID NO. 31-SEQ ID NO. 33;
the target sequence of the shRNA and/or shRNA-miR of the target HLA-DRB5 is selected from one of SEQ ID NO. 34-SEQ ID NO. 36;
the target sequence of the shRNA and/or shRNA-miR of the target HLA-DQA1 is selected from one of SEQ ID NO. 37-SEQ ID NO. 39;
the target sequence of the shRNA and/or shRNA-miR of the target HLA-DQB1 is selected from one of SEQ ID NO. 40-SEQ ID NO. 42;
the target sequence of the shRNA and/or shRNA-miR of the target HLA-DPA1 is selected from one of SEQ ID NO. 43-SEQ ID NO. 45;
the target sequence of the shRNA and/or shRNA-miR of the target HLA-DPB1 is selected from one of SEQ ID NO. 46-SEQ ID NO. 48.
In the first to fourth aspects of the present invention, further, the genome of the pluripotent stem cell or the derivative thereof further comprises shR NA and/or miRNA processing complex-associated gene and/or anti-interferon effector molecule, wherein: the shRNA and/or miRNA processing complex related gene comprises at least one of Drosha, Ago1, Ago2, Dicer1, Exportin-5, TRBP (TARBP2), PACT (PRKRA) and DGCR 8; the anti-interferon effector molecule is shRNA and/or s hRNA-miR of at least one of target PKR, 2-5As, IRF-3 and IRF-7.
Furthermore, the target sequence of the shRNA and/or shRNA-miR targeting the PKR is selected from one of SEQ ID NO. 49-SEQ ID NO. 51;
the target sequence of the shRNA and/or shRNA-miR targeting 2-5As is selected from one of SEQ ID NO. 52-SEQ ID NO. 60;
the target sequence of the target IRF-3 shRNA and/or shRNA-miR is selected from one of SEQ ID NO. 61-SEQ ID NO 63;
the target sequence of the shRNA and/or shRNA-miR of the target IRF-7 is selected from one of SEQ ID NO. 64-SEQ ID NO. 66.
With regard to the third and fourth aspects of the present invention, the inducible gene expression system includes at least one of a Tet-Off system, a dimer inducible expression system.
When the inducible gene expression system employed is the Tet-Off system, the expression of small nucleic acid molecules in the cell or derivative thereof can be controlled by the addition of the exogenous inducer tetracycline (Doxycyline, Dox). After the pluripotent stem cells or the derivatives thereof are transplanted into a donor, the expression level of the small nucleic acid molecules can be gradually reduced even by adjusting the addition amount of Dox, so that the cells can gradually express low-concentration immune-related genes to stimulate the donor, and the donor can gradually generate tolerance to the transplanted cells or the derivatives thereof, and finally stable tolerance is achieved. In general, Dox is added in an amount of 0 to 100 uM.
The dimer inducible expression system specifically refers to: dimerized inducers or dimers are used to recombine active transcription factors on inactive fusion proteins. The most commonly used system is rapamycin (rapamydn), a natural product, or an analog that is biologically inactive, as the drug for dimerization. The rapamycin (or analog) sibling protein FKBP12 (the protein to which FKBP binds to FK 506) and a large serine-threonine protein kinase, known as FRAP (FRBP-rapamycin associated protein, mTOR (mammalian target of rapamycin)), have high affinity and function to bind to both proteins, thus bringing them together as a heterologous dimer. To regulate transcription of a target gene, a DNA binding domain is fused to one or more FKBP domains and a transcription repressing domain is fused to amino acid position 93 of FRAP, designated FRB, which is sufficient to bind the FKBP-rapamycin complex. Dimerization of these two fusion proteins can only occur in the presence of rapamycin. Thus inhibiting transcription of genes having sites that bind to the DNA binding region.
In the first to fourth aspects of the present invention, further, the genome of the above-mentioned pluripotent stem cell or the derivative thereof further introduces an exosome-processing synthetic gene comprising at least one of STEAP3, Syndevan-4, an L-aspartate oxidase fragment (SEQ ID No.69), CD63-L7Ae (SEQ ID No.70) and Cx 43S 368A.
The secretion efficiency of the exosome and the encapsulation efficiency of shRNA, shRNA-miR and mature siRNA can be improved by introducing the exosome processing synthetic gene into the genome of the stem cell or the stem cell derivative.
In relation to the first to fourth aspects of the present invention, further, the expression frameworks of the shRNA and/or shRNA-miR targeting IL-4R α, major histocompatibility complex gene, major histocompatibility complex-related gene, PKR, 2-5As, IRF-3 or IRF-7 are As follows:
(1) shRNA expression framework: the gene sequence sequentially comprises an shRNA sequence, a stem-loop sequence, a reverse complementary sequence of the shRNA sequence and Poly T from 5 'to 3'; the two reverse complementary target sequences are separated by a middle stem-loop sequence to form a hairpin structure, and finally Poly T is connected to be used as a transcription terminator of RNA polymerase III;
(2) shRNA-miR expression framework: replacing a target sequence in the microRNA-30 or the microRNA-155 with a shRNA-miR target sequence to obtain the target sequence.
In the first to fourth aspects of the present invention, further, the expression sequence of the shRNA and/or shRNA-miR targeting IL-4R α, the expression sequence of the first nucleic acid molecule, the immune-compatible molecule, the gene related to the shRNA and/or miRNA processing complex, the anti-interferon effector molecule, the inducible gene expression system, and the method for introducing the exosome processing synthetic gene are methods using viral vector interference, non-viral vector transfection, or gene editing, and the method of gene editing is preferably gene knock-in.
In the first to fourth aspects of the present invention, further, the expression sequence of the IL-4R α -targeting shRNA and/or shRNA-miR, the first nucleic acid molecule, the exosome processing synthetic gene, the expression sequence of the immune-compatible molecule, the introduction site of the shRNA and/or miRNA processing complex-related gene, the anti-interferon effector molecule, the inducible gene expression system is a genome safety site, preferably one or more of an AAVS1 safety site, an eGSH safety site, and an H11 safety site.
With respect to the first to fourth aspects of the present invention, further, the pluripotent stem cells include embryonic stem cells, embryonic germ cells, embryonic carcinoma cells, or induced pluripotent stem cells;
the pluripotent stem cell derivative comprises an adult stem cell, each germ layer cell or a tissue or organ into which the pluripotent stem cell is differentiated;
the adult stem cells include mesenchymal stem cells or neural stem cells.
In a fifth aspect of the invention, an exosome is provided, which is secreted by the pluripotent stem cell or a derivative thereof.
In a sixth aspect of the present invention, there is provided a use of said pluripotent stem cell or a derivative thereof and/or said exosome for the preparation of an anti-allergic, atopic dermatitis and/or anti-asthma therapeutic drug.
The invention has the beneficial effects that:
1. the pluripotent stem cells or the derivatives thereof provided by the first aspect of the invention can be applied to autologous cell-induced iPSCs or MSCs low-immunogenicity cells. After the expression sequence of shRNA and/or shRNA-miR of the targeted IL-4R alpha is introduced into the genome of iPSCs induced by autologous cells, the iPSCs can express a large amount of shRNA and/or shRNA-miR of the targeted IL-4R alpha and are wrapped by exosomes secreted by the cells. The exosome carries the inhibitory factors to be combined with target cells and then releases the inhibitory factors, thereby inhibiting the expression of IL-4R alpha and achieving the effect of treating allergy, atopic dermatitis, asthma and other related diseases.
2. The pluripotent stem cells or derivatives thereof provided by the second aspect of the invention may also be used in allogeneic cell therapy. Because the B2M and CIITA genes in the pluripotent stem cells or the derivatives thereof are knocked out, the pluripotent stem cells or the derivatives thereof have low immunogenicity, and when the pluripotent stem cells or the derivatives thereof are transplanted into a recipient, RNA interference of the genes related to the immune response, which is mediated by transcription products of the small nucleic acid molecules and the second nucleic acid molecules, coded by the first nucleic acid molecules only acts on donor cells, and cannot interfere with the genome of the recipient cells. Improving the immune compatibility between the graft and the recipient. The transplant can continuously express shRNA and/or shRNA-miR of the target IL-4R alpha in a receptor endogenesis, after the inhibition factors are wrapped by the exosomes, the exosomes carry the inhibition factors to be combined with target cells, and then the inhibition factors are released, so that the expression of the IL-4R alpha is inhibited, and the effect of treating allergy, atopic dermatitis, asthma and other related diseases is achieved.
3. The pluripotent stem cells or derivatives thereof provided by the third aspect of the invention have immune compatibility, and can eliminate or reduce allogeneic immune rejection response. Furthermore, the RNA interference program of the pluripotent stem cell or the derivative thereof acts only on such an engineered pluripotent stem cell or the derivative thereof. Thus, when such cells or derivatives are transplanted into a recipient, RNA interference directed to a gene associated with an immune response mediated by the transcript of the small nucleic acid molecule encoded by the first nucleic acid molecule and the second nucleic acid molecule acts only on the donor cell and does not interfere with the genome of the recipient cell.
Furthermore, an inducible gene expression system is introduced into the genome of the pluripotent stem cell or the derivative thereof, and is used for regulating the expression of the first nucleic acid molecule, so that the immune compatibility and reversibility of the pluripotent stem cell or the derivative thereof are realized.
4. The pluripotent stem cell or the derivative thereof provided by the fourth aspect of the invention has an immune-compatible molecule expression sequence introduced into its genome, so that the pluripotent stem cell or the derivative thereof has low immunogenicity, and when the pluripotent stem cell or the derivative thereof is transplanted into a recipient, RNA interference directed to an immune response-related gene mediated by a transcription product of a small nucleic acid molecule encoded by a first nucleic acid molecule and a second nucleic acid molecule only acts on a donor cell, and does not interfere with the genome of the recipient cell. Improving the immune compatibility between the graft and the recipient. The transplant can continuously express shRNA and/or shRNA-miR of the target IL-4R alpha in a receptor endogenesis, after the inhibition factors are wrapped by the exosomes, the exosomes carry the inhibition factors to be combined with target cells, and then the inhibition factors are released, so that the expression of the IL-4R alpha is inhibited, and the effect of treating allergy, atopic dermatitis, asthma and other related diseases is achieved.
Furthermore, the genome of the pluripotent stem cell or the derivative thereof provided by the fourth aspect of the invention is also introduced with an inducible gene expression system, the inducible gene expression system can regulate and control the expression of the immune compatible molecules, and the inducible gene expression system is regulated and controlled by an exogenous inducer, so that the on and off of the inducible gene expression system are controlled by adjusting the addition amount, the sustained action time and the type of the exogenous inducer, and the expression quantity of the expression sequence of the immune compatible molecules is further controlled, thereby realizing the reversible regulation and control of the immune compatibility of the pluripotent stem cell or the derivative thereof. When the inducible gene expression system is started, the transcription product of the small molecule nucleic acid which is normally expressed and a second nucleic acid molecule which is introduced into the 3' UTR region of the immune response related gene is specifically combined, so that an RNA interference program is started, mRNA of the immune response related gene is degraded or silenced, and the expression of the immune response related gene is blocked. Thus, when such cells or derivatives are transplanted into a recipient, the allogeneic immune rejection response may be eliminated or reduced, and the immune compatibility between the transplant and the recipient may be improved. When the graft suffers from pathological changes, the inducible gene expression system can be closed by adding an exogenous inducer, so that the expression of small nucleic acid molecules and the interference effect of the small nucleic acid on mRNA of the immune response related gene are stopped, the normal expression of the immune related gene is recovered, the antigen presenting capability of graft cells is further recovered, and the receptor can remove the pathological graft, thereby improving the clinical safety of the pluripotent stem cells or the derivatives thereof, and greatly expanding the value of the pluripotent stem cells or the derivatives thereof in clinical application.
5. The pluripotent stem cells or the derivatives thereof can also gradually reduce the expression quantity of small nucleic acid molecules in the pluripotent stem cells or the derivatives thereof by adjusting the addition quantity and the lasting action time of the exogenous inducer, so that the donor cells can gradually express low-concentration immune related genes to stimulate the donor, thereby gradually generating tolerance to transplanted cells or the derivatives thereof by the donor, and finally achieving stable tolerance. In this case, even though mismatched HLA class I molecules are expressed on the surface of the graft cells, they are compatible with the recipient immune system.
Drawings
Figure 1 is a plasmid map of Cas9 (D10A).
FIG. 2 is a plasmid map of sgRNA Clone AAVS 1-1.
FIG. 3 is a plasmid map of sgRNA Clone AAVS 1-2.
FIG. 4 is a plasmid map of sgRNA clone B2M-1.
FIG. 5 is a plasmid map of sgRNA clone B2M-2.
FIG. 6 is a plasmid map of sgRNA clone B2M-3.
FIG. 7 is a plasmid map of sgRNA clone B2M-4.
FIG. 8 is a plasmid map of sgRNA clone CIITA-1.
FIG. 9 is a plasmid map of sgRNA clone CIITA-2.
FIG. 10 is a plasmid map of sgRNA clone CIITA-3.
FIG. 11 is a plasmid map of sgRNA clone CIITA-4.
FIG. 12 is a plasmid map of AAVS1KI Vector (shRNA, constitutive).
FIG. 13 is a plasmid map of AAVS1KI Vector (shRNA, inducible).
FIG. 14 is a plasmid map of AAVS1KI Vector (shRNA-miR, constitutive).
FIG. 15 is a plasmid map of AAVS1KI Vector (shRNA-miR, inducible).
FIG. 16 is a plasmid map of B2M KI Vector.
FIG. 17 is a plasmid map of CIITA KI Vector.
Detailed Description
The present invention will be described in further detail with reference to the following specific embodiments and accompanying drawings.
It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
Experimental procedures without specific conditions noted in the following examples, generally followed by conventional conditions, such as Sambrook et al, molecular cloning: the conditions described in the Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the manufacturer's recommendations. The various chemicals used in the examples are commercially available.
1 Experimental materials and methods
1.1 shRNA and/or shRNA-miR targeting IL-4R alpha
The target sequences of the shRNA and/or shRNA-miR targeting IL-4R alpha are shown in Table 1.
TABLE 1 target sequences for shRNA and/or shRNA-miR targeting IL-4R alpha
In the experimental schemes in tables 8-9 below, the knockin shRNAs and/or shRNA-miR targeting IL-4R alpha of each experimental group are shRNAs or shRNA-miR constructed by using the target sequence 1 in Table 1. Those skilled in the art will understand that: the technical effects of the invention can be realized by the shRNA and/or shRNA-miR of the target IL-4R alpha constructed by other target sequences, and the shRNA and/or shRNA-miR also fall into the protection scope of the claims of the invention.
1.2 pluripotent Stem cells or derivatives thereof
The pluripotent stem cells can be selected from Embryonic Stem Cells (ESCs), Induced Pluripotent Stem Cells (iPSCs) and other forms of pluripotent stem cells, such as hPSCs-MSCs, NSCs, EBs cells. Wherein:
ESCs: HN4 cells were selected and purchased from Shanghai department of sciences.
And (3) iPSCs: using a third generation highly efficient and safe episomal-iPSCs induction system (6F/BM1-4C) established by us, pE3.1-OG-KS and pE3.1-L-Myc-hmiR 302 cluster are transferred into somatic cells through electricity, RM1 is cultured for 2 days, BioCISO-BM1 containing 2uM Parnate is cultured for 2 days, BioCISO-BM1 containing 2uM Parnate, 0.25mM sodium butyrate, 3uM CHIR99021 and 0.5uM PD03254901 is cultured for 2 days, iPSCs clones can be picked up after being cultured to about 17 days by using a dry cell culture medium BioCISO, and the picked iPSCs clones are purified, digested and passaged to obtain stable iPSCs. The specific construction method is as follows: stem Cell Res ther.2017nov 2; 8(1):245.
hPSCs-MSCs: iPSCs are cultured for 25 days by using a stem cell culture medium (BioCISO containing 10uM TGF beta inhibitor SB431542), during which digestion passage (2mg/mL Dispase digestion) is carried out at 80-90 confluence, passage is carried out at 1:3 into a Matrigel coated culture plate, then ESC-MSC culture medium (knockkockout DMEM culture medium containing 10% KSR, NEAA, diabody, glutamine, beta-mercaptoethanol, 10ng/mL bFGF and SB-431542) is cultured, fluid is changed every day, passage is carried out at 80-90 confluence (passage is carried out at 1: 3), and continuous culture is carried out for 20 days. The specific construction method is as follows: proc Natl Acad Sci U S A.2015; 112(2):530-535.
NSCs: iPSCs are cultured for 14 days by using an induction medium (knockout DMEM medium containing 10% KSR, TGF-beta inhibitor and BMP4 inhibitor), rose annular nerve cells are picked up and cultured in a low-adhesion culture plate, the medium is cultured by using D MEM/F12 (containing 1% N2 and Invitrogen) and Neurobasal medium (containing 2% B27 and Invitrogen) in a ratio of 1:1, 20ng/ml bFGF and 20ng/ml EGF, and digestion is carried out by using Accutase for digestion and passage. The specific construction method is as follows: FASEB J.2014; 28(11):4642-4656.
EBs cells: digesting iPSCs with the confluency of 95% for 6min by using BioC-PDE1, scraping the cells into blocks by using a mechanical scraping method, settling cell agglomerates, transferring the settled cell agglomerates into a low-adhesion culture plate, culturing for 7 days by using BioCISO-EB1, and changing the liquid every other day. After 7 days, the cells were transferred to a Matrigel-coated plate and adherent culture was continued using BioCISO, and Embryoid Bodies (EBs) having an inner, middle and outer mesoderm structure were obtained after 7 days. The specific construction method is as follows: stem Cell Res ther.2017nov 2; 8(1):245.
The pluripotent stem cell derivative also includes adult stem cells, each germ layer cell or tissue, organ into which the pluripotent stem cells are differentiated; the adult stem cells include mesenchymal stem cells or neural stem cells.
1.3 Small nucleic acid molecules and corresponding first nucleic acid molecule, second nucleic acid molecule
The sequence of the small nucleic acid molecule is a random sequence derived from a non-human species that does not target any mRNA or lncRNA from humans, preferably from caenorhabditis elegans.
The sequence of the small nucleic acid molecule used in this example was
5’-TTGTACTACACAAAAGTACTG-3’(SEQ ID NO.1);
Designing a first nucleic acid molecule and a second nucleic acid molecule according to the small nucleic acid molecules, wherein the first nucleic acid molecule and the second nucleic acid molecule are respectively as follows:
a first nucleic acid molecule (i.e., the shRNA expression framework or shRNA-miR expression framework of a small nucleic acid molecule):
(1) the sequence composition of the shRNA expression framework of the small nucleic acid molecule is as follows:
5’-CCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGCTCGGTACCCGGGTCGAGGTAGGCGTGTACGGTGGGAGGCCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTGCTAGCGCCACC(SEQ ID NO.2)N1...N21TTCAAGAGA(SEQ ID NO.3)N22...N42TTTTTT-3’。
wherein the content of the first and second substances,
a)N1...N21is the sequence of the small nucleic acid molecule, N22...N42The reverse complementary sequence of the small nucleic acid molecule sequence;
b) if the plasmid needs to express shRNAs of a plurality of genes, each gene corresponds to a shRNA expression frame and then is connected seamlessly;
c) constitutive shRNA plasmids with different resistance genes only have different resistance genes and have the same other sequences;
d) n represents A or T or G or C base.
(2) shRNA-miR expression framework of small nucleic acid molecules: the small nucleic acid molecule sequence is used for replacing a target sequence in microRNA-30 or microRNA-155 to obtain the target sequence. The specific sequence is as follows:
5’-GAGGCTTCAGTACTTTACAGAATCGTTGCCTGCACATCTTGGAAACACTTGCTGGGATTACTTCTTCAGGTTAACCCAACAGAAGGCTAAAGAAGGTATATTGCTGTTGACAGTGAGCG(SEQ ID NO.4)M1N1...N21TAGTGAAGCCACAGATGTA(SEQ ID NO.5)N22...N42M2TGCCTACTGCCTCGGACTTCAAGGGGCTACTTTAGGAGCAATTATCTTGTTTACTAAAACTGAATACCTTGCTATCTCTTTGATACATTTTTACAAAGCTGAATTAAAATGGTATAAAT(SEQ ID NO.6)-3’。
wherein, the first and the second end of the pipe are connected with each other,
a)N1...N21is a small nucleic acid molecule sequence, N22...N42Is a reverse complementary sequence of a small nucleic acid molecule sequence;
b) if the plasmid needs to express shRNA-miR of a plurality of genes, each gene corresponds to a shRNA-miR expression frame and is then connected seamlessly;
c) constitutive shRNA-miR plasmids with different resistance genes only have different resistance genes, and other sequences are the same;
d) n represents A or T or G or C base, M base represents A or C base;
e) if N1 is G base, then M1Is A base; otherwise M1Is a C base;
f)M1base and M2And (3) base complementation.
A second nucleic acid molecule: comprises a reverse complementary sequence of at least 3 repeated small nucleic acid molecule sequences, preferably a reverse complementary sequence of 6-10 repeated small nucleic acid molecule sequences. The reverse complement of the small nucleic acid molecule sequence can be linked by a random Linker sequence.
As an embodiment of the present invention, the second nucleic acid molecule is formed by connecting the first 10nt random sequence and the reverse complement of 8 repeated small nucleic acid molecule sequences through a random linker sequence (CGTA):
atTCTAGATACAGTACTTTTGTGTAGTACAACGTACAGTACTTTTGTGTAGTACAACGTACAGTACTTTTGTGTAGTACAACGTACAGTACTTTTGTGTAGTACAACGTACAGTACTTTTGTGTAGTACAACGTACAGTACTTTTGTGTAGTACAACGTACAGTACTTTTGTGTAGTACAACGTACAGTACTTTTGTGTAGTACAACGTA(SEQ ID NO.7)。
1.4 genomic safety sites
In the technical scheme of the invention, the genome safety locus for knocking-in the gene can be selected from an AAVS1 safety locus, an eGSH safety locus or other safety loci:
(1) AAVS1 safety site
The AAVS1 site (the alias "PPP 1R2C site") is located on chromosome 19 of the human genome and is a verified "safe harbor" site that ensures the desired function of the transferred DNA fragment. The site is an open chromosome structure, can ensure that the transgene can be normally transcribed, and has no known side effect on cells when the exogenous target segment is inserted into the site.
(2) eGSH safe site
The eGSH safe site is located on chromosome 1 of the human genome, and is another 'safe harbor' site which can ensure the expected function of the transferred DNA fragment after the paper verifies.
(3) Other safety sites
The H11 safe site (also called Hipp11) is located on the number 22 chromosome of a human, is a site between two genes Eif4enif1 and Drg1, is discovered and named in 2010 by Simon Hippenmeyer, and has little risk of influencing endogenous gene expression after the insertion of a foreign gene because the H11 site is located between the two genes. The H11 site was verified to be a safe transcriptional activation region between genes, a new "safe harbor" site outside the AAVS1, eGS H sites.
1.5 inducible Gene expression System
The inducible gene expression system is selected from the group consisting of: tet-Off system or dimer-Off expression system:
(1) tet-Off system
In the absence of tetracycline, the tTA protein continues to act on the tet promoter, resulting in sustained gene expression. This system is very useful in situations where it is desirable to maintain the transgene in a sustained expression state. When tetracycline is added, the tetracycline can change the structure of the tTA protein, so that the tTA protein cannot be combined with a promoter, and the expression level of a gene driven by the tTA protein is reduced. To keep the system in an "off" state, the tetracycline must be added continuously.
The invention knocks the sequence of the tet-Off system and one or more immune compatible molecules into the genome safety site of the pluripotent stem cell, and accurately turns on or Off the expression of the immune compatible molecules through the addition of tetracycline, thereby reversibly regulating the expression of major histocompatibility complex related genes in the pluripotent stem cell or the derivative thereof.
(2) Dimer-switched off expression system
Dimer-mediated gene expression regulation system: there are many ways of chemically regulating transcription of target genes, most commonly regulated using allosteric modulators that influence the activity of transcription factors. One such method is the use of dimerizing inducers or dimers to recombine active transcription factors on inactive fusion proteins. The most commonly used system is rapamycin (rapamydn), a natural product, or an analog that is biologically inactive, as the drug for dimerization. The rapamycin (or analog) sibling protein FKBP12 (the protein to which FKBP binds to FK 506) and a large serine-threonine protein kinase, known as FRAP [ FRBP-rapamycin associated protein, mTOR (mammalian target of rapamycin), have high affinity and function to bind to both proteins, thus bringing them together as a heterologous dimer. To regulate transcription of a target gene, a DNA binding domain is fused to one or more FKBP domains and a transcription repressing domain is fused to amino acid position 93 of FRAP, designated FRB, which is sufficient to bind the FKBP-rapamycin complex. Dimerization of these two fusion proteins can only occur in the presence of rapamycin. Thus inhibiting transcription of genes having sites that bind to the DNA binding region.
1.6 immune compatible molecules
The immune compatible molecules can regulate the expression of allogeneic immune rejection related genes in the pluripotent stem cells or derivatives thereof. The types and sequences of specific immune-compatible molecules are shown in table 2.
TABLE 2 immune-compatible molecules
The target sequences of the shRNA or shRNA-miR immune compatible molecules are shown in Table 3.
TABLE 3 sequences of shRNA or shRNA-miR
In the experimental schemes in tables 8 to 9 below, the knockin shRNA or shRNA-miR immune-compatible molecules in each experimental group are shRNA or shRNA-miR constructed by using the target sequence 1 in table 3. Those skilled in the art will understand that: the shRNA or shRNA-miR immune compatible molecule constructed by other target sequences can also realize the technical effect of the invention and all the shRNA or shRNA-miR immune compatible molecule fall into the protection scope of the claims of the invention.
1.7 shRNA/miRNA processing Complex genes and anti-Interferon Effector molecules
The primary miRNA (pri-miRNA) in the nucleus is microprocessed through the complex Drosha-DGCR8, which cleaves the pri-miRNA into a precursor miRNA (pre-miRNA), which then forms a hairpin. Then, the pre-miRNA is transported out of the nucleus via the Exportin-5-Ran-GTP complex. The RNase Dicer enzyme, which binds to the double-stranded RNA-binding protein TRBP (TARBP2) in the cytoplasm, breaks down the pre-miRNA into mature lengths, at which time the miRNA is still in a double-stranded state. Finally, it is transported into AGO2 to form RISC (RNA-induced silencing complex). Finally, one strand of the miRNA double strand is retained in the RISC complex, and the other strand is eliminated and rapidly degraded. While DGCR8, the main binding protein of Drosha, can bind to pri-miRNA through two double-stranded RNA binding regions at its C-terminal end, recruit and guide Drosha to cut at the right position of pri-miRNA to produce pre-miRNA, which is further cut by Dicer and TRBP/PACT processing to form mature miRNA. Deletion or abnormal expression of DGCR8 affects the cleavage activity of Drosha, which in turn affects the activity of miRNA, leading to disease. TRBP is able to recruit Dicer complex mirnas to form RISC Ago 2.
According to the invention, by using a gene knock-in technology, when the shRNA-miR expression sequences aiming at HLA class I molecules, HLA class II molecules and the like which can be induced to close expression are knocked in at a genome safety site, preferably, shRNA and/or miRNA processing machines which can be induced to close expression are knocked in at the same time, wherein the shRNA and/or miRNA processing machines comprise Drosha (access number: NM-001100412), Ago1(access number: NM-012199), Ago2(access number: NM-001164623), Dicer1(access number: NM-001195573), export-5 (access number: NM-020750), TRBP (access number: NM-134323), PACT (access number: NM-003690) and DGCR8(access number: NM-022720), so that cells do not occupy the processing of other miRNAs and influence the cell functions.
In addition, during IFN induction, double-stranded RNA-dependent Protein Kinase (PKR), which is a key factor of the whole cell signal transduction pathway, and 2 ', 5' Oligoadenylate Synthetase (2,5-Oligoadenylate Synthetase,2-5As), which are closely related to dsRNA-induced IFN, are involved. PKR can inhibit protein synthesis by phosphorylating eukaryotic cell transcription factors, arrest cells in G0/G1 and G2/M phases and induce apoptosis, while dsRNA can promote synthesis of 2-5As, which results in nonspecific activation of RNase, RNaseL, degradation of all mRNA in cells and cell death. The specificity of induction of type I interferons is achieved by members of the IRF transcription factor family, which are not inducible to be secreted in many viral infections in the absence of IRF-3 and IRF-7 expression in cells. Lack of IFN response, in order to recover, requires the two proteins were expressed together.
According to the invention, by utilizing a gene knock-in technology, when an immune compatible molecule shRNA-miR expression sequence is knocked in at a genome safety site, shRNA and/or shRNA-miR expression sequences which can induce closed expression and aim at inhibiting PKR, 2-5As, IRF-3 and IRF-7 genes are/is preferably knocked in at the same time, so that interferon reaction induced by dsRNA is reduced, and cytotoxicity is avoided.
The sequence of the insertion positions of the shRNA/miRNA processing complex related gene, the anti-interferon effector molecule and the immune compatible molecule at the genome safety site is not limited, and the shRNA/miRNA processing complex related gene, the anti-interferon effector molecule and the immune compatible molecule can be arranged in any sequence without mutual interference or influence on the structure and the function of other genes of the genome.
Specific target sequences for anti-interferon effector molecules are shown in table 4.
TABLE 4 target sequences for interferon effector molecules
In the anti-interferon effector molecule knock-in schemes of tables 8 to 9 below, the anti-interferon effector molecules of each experimental group were all anti-interferon effector molecules constructed using target sequence 1 in table 4. Those skilled in the art will understand that: the anti-interferon effector molecules constructed by other target sequences can also achieve the technical effects of the invention and fall into the protection scope of the claims of the invention.
1.8 Universal framework for Immunocompatible molecules, shRNA or shRNA-miR of anti-Interferon Effector molecules
The general framework sequences of the shRNA or shRNA-miR of the immune compatible molecules and the anti-interferon effector molecules are as follows:
(1) the constitutive expression framework of shRNA is:
GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGCTAGCGCCACC(SEQ ID NO.67)N1...N21TTCAAGAGA(SEQ ID NO.3)N22...N42TTTTTT;
wherein:
a、N1...N21shRNA target sequence for the corresponding Gene, N22...N42Is a reverse complementary sequence of the shRNA target sequence of the corresponding gene;
b. if the plasmid needs to express shRNAs of a plurality of genes, each gene corresponds to a shRNA expression frame and then is connected seamlessly;
c. constitutive shRNA plasmids with different resistance genes only have different resistance genes and have the same other sequences;
d. n represents A, T, G, C bp;
e. SEQ ID NO.67 is the U6 promoter sequence;
f. SEQ ID NO.3 is a stem-loop sequence.
(2) The shRNA inducible expression framework is as follows:
GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGTTTACCACTCCCTATCAGTGATAGAGAAAAGTGAAAGTCGAGCTCGGTACCCGGGTCGAGGTAGGCGTGTACGGTGGGAGGCCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTGCTAGCGCCACC(SEQ ID NO.68)N1...N21TTCAAGAGA(SEQ ID NO.3)N22...N42TTTTTT;
wherein:
a、N1...N21shRNA target sequence of the corresponding Gene, N22...N42Is a reverse complementary sequence of the shRNA target sequence of the corresponding gene;
b. if the plasmid needs to express shRNAs of a plurality of genes, each gene corresponds to a shRNA expression frame and then is connected seamlessly;
c. constitutive shRNA plasmids with different resistance genes only have different resistance genes and have the same other sequences;
d. n represents A, T, G, C bp;
e. SEQ ID NO.68 is the H1 TO promoter sequence;
f. SEQ ID NO.3 is a stem-loop sequence.
(3) The shRNA-miR constitutive or inducible expression framework is as follows:
the shRNA-miR target sequence is used for replacing a target sequence in microRNA-30 to obtain the shRNA-miR target sequence, and the specific sequence is as follows:
GAGGCTTCAGTACTTTACAGAATCGTTGCCTGCACATCTTGGAAACACTTGCTGGGATTACTTCTTCAGGTTAACCCAACAGAAGGCTAAAGAAGGTATATTGCTGTTGACAGTGAGCG(SEQ ID NO.4)M1N1...N21TAGTGAAGCCACAGATGTA(SEQ ID NO.5)N22...N42M2TGCCTACTGCCTCGGACTTCAAGGGGCTACTTTAGGAGCAATTATCTTGTTTACTAAAACTGAATACCTTGCTATCTCTTTGATACATTTTTACAAAGCTGAATTAAAATGGTATAAAT(SEQ ID NO.6);
wherein:
a、N1...N21shRNA-miR target sequence, N, as a corresponding gene22...N42Is a reverse complementary sequence of shRNA-miR target sequence of a corresponding gene;
b. if the plasmid needs to express shRNA-miR of a plurality of genes, each gene corresponds to a shRNA-miR expression frame and is then connected seamlessly;
c. constitutive shRNA-miR plasmids with different resistance genes only have different resistance genes, and other sequences are the same;
d. m is A or C, N is A, T, G, C;
e. if N is present1Is a G base, then M1Is A base; otherwise M1Is a C base;
f、M1base and M2And (3) base complementation.
1.9 synthetic Gene processing by exosome
The exosome processing synthetic gene is selected from at least one of STEAP3(NM _182915), Syndecano-4 (NM _002999), L-aspartate oxidase fragment (SEQ ID NO.69), CD63-L7Ae (SEQ ID NO.70) and Cx 43S 368A. Wherein Cx 43S 368A is obtained by mutating S (serine) to A (alanine)) at position 368 of Cx43 (NM-000165).
1.10 Gene editing System, Gene editing method and inspection method
1.10.1 Gene editing System
The gene editing technology adopts a CRISPR-Cas9 gene editing system. The Cas9 protein used was Cas9(D10A), Cas9(D10A) bound to sgrnas responsible for specific recognition of the target sequence (genomic DNA) which was then single-stranded cleaved by Cas9 (D10A). Double Strand breaks in genomic DNA (DSB) must occur, and two Cas 9(D10A)/sgRNA must cleave the two strands of genomic DNA separately, and not too far apart. The Cas 9(D10A)/sgRNA scheme has the advantage of higher specificity and lower probability of off-target compared to the Cas 9/sgRNA scheme. The plasmids or Donor fragments used in the gene editing system were: cas9(D10A) plasmid, sgRNA clone plasmid, Donor fragment.
(1) Cas9(D10A) plasmid: a plasmid expressing the Cas9(D10A) protein, specifically single-stranded cleaving genomic DNA under the direction of sgrnas.
(2) sgRNA plasmid: a plasmid for expressing sgRNA, sgRNA (small guide RNA), is a guide RNA (guide RNA, gRNA) responsible for directing targeted cleavage of the expressed Cas9(D10A) protein at gene editing.
The sgRNA sequences of AAVS1, B2M, CIITA are as follows:
sgRNA-AAVS1-1:5’-TATAAGGTGGTCCCAGCTCGGGG-3’(SEQ ID NO.71);
sgRNA-AAVS1-2:5’-AGGGCCGGTTAATGTGGCTCTGG-3’(SEQ ID NO.72)。
sgRNA-B2M-1:5’-CTCCTGTTATATTCTAGAACAGG-3’(SEQ ID NO.73);
sgRNA-B2M-2:5’-TTTCAGCATCAATGTACCCTGGG-3’(SEQ ID NO.74);
sgRNA-B2M-3:5’-CGCGAGCACAGCTAAGGCCA-3’(SEQ ID NO.75);
sgRNA-B2M-4:5’ACTCTCTCTTTCTGGCCTGG 3’(SEQ ID NO.76)。
sgRNA-CIITA-1:5’-GGCACTCAGAAGACACTGATGGG-3’(SEQ ID NO.77);
sgRNA-CIITA-2:5’-AAGGTGTCTGGTCGGAGAGCAGG-3’(SEQ ID NO.78);
sgRNA-CIITA-3:5’-ACCCAGCAGGGCGTGGAGCC-3’(SEQ ID NO.79);
sgRNA-CIITA-4:5’-GTCAGAGCCCCAAGGTAAAA-3’(SEQ ID NO.80)。
(3) donor fragment: the two ends contain recombination arms which are respectively positioned at the left and the right sides of the broken position of the genome DNA, and the middle contains genes, fragments or expression elements needing to be inserted. In the presence of the Donor fragment, the cells undergo a Homologous Recombination (HR) reaction at the site of the genomic break. If the Donor fragment is not added, Non-homologous End Joining-NHEJ reaction occurs at the site of the genomic break in the cell. This fragment was obtained by digesting KI (Knock-in, the same applies hereinafter) Vector plasmid and recovering it.
AAVS1, B2M, CIITA homology arms are as follows:
(1) the nucleotide sequences of AAVS1 homologous arms AAVS1-HR-L and AAVS1-HR-R are respectively shown as SEQ ID NO.81 and SEQ ID NO. 82;
(2) the nucleotide sequences of B2M homologous arms B2M-HR-L and B2M-HR-R are respectively shown as SEQ ID NO.83 and SEQ ID NO. 84;
(3) the nucleotide sequences of CIITA-HR-L and CIITA-HR-R of the CIITA homologous arm are respectively shown in SEQ ID NO.85 and SEQ ID NO. 86.
1.10.2 constitutive plasmid and inducible plasmid
Constitutive plasmid: the expression function of the Donor fragment obtained from the constitutive plasmid cannot be regulated after knocking in the genomic DNA.
Inducible plasmids: after knocking in the genomic DNA, the expression function of the Donor fragment obtained from the inducible plasmid can be controlled by adding an inducer, which is equivalent to adding a switch for turning on or off the expression function.
1.10.3 plasmid construction method
(1) Cas9(D10A) plasmid: this Plasmid no longer needs to be constructed and is ordered directly from Addgene (Plasmid 41816, Addgene).
(2) sgRNA plasmid: the original blank Plasmid is ordered from Addge (Plasmid 41824, Addge), then the DNA sequence is input in the website (URL: https:// ccttop. cos. uni-heidelberg. de) to design the target sequence, and finally different target sequences are respectively put into the blank sgRNA Plasmid to complete the construction.
(3) KI Vector plasmid:
acquisition of Amp (R) -pUC origin fragment: designing PCR primers, and amplifying and recovering the fragment by using a high fidelity enzyme (Nanjing Nozaki organism, P505-d1) through a PCR method by using a pUC18 plasmid as a template;
acquisition of aavs1 or eGSH recombination arms: extracting human cell genome DNA and designing corresponding primer, then using human genome DNA as template and using high fidelity enzyme (Nanjing Nozan organism, P505-d1) to amplify and recover such fragments AAVS1, B2M and CIITA homologous arm (AAVS1-HR-L, AAVS1-HR-R, B2M-HR-L, B2M-HR-R, CIITA-HR-L and CIITA-HR-R) by PCR method;
c. acquisition of the individual plasmid elements: designing PCR amplification primers of each element, and then respectively amplifying and recovering each plasmid element by using a plasmid containing the element as a template and using a high fidelity enzyme (Nanjing NuoZanza, P505-d1) through a PCR method;
d. assembly into a complete plasmid: the fragments obtained in the previous step were ligated together using a multi-fragment recombinase (Nanjing Nozam, C113-02) to form a complete plasmid.
The plasmid map of Cas9(D10A) obtained by the method is shown in figure 1, the plasmid map of sgRNA of AAVS1 safety site is shown in figure 2-3, the plasmid map of sgRNA of B2M gene is shown in figure 4-7, the plasmid map of sgRNA of CIITA gene is shown in figure 8-11, the plasmid map (constitutive and inducible) of constructed AAVS1KI is shown in figure 12-15, the plasmid map of B2M KI is shown in figure 16, and the plasmid map of CIITA KI is shown in figure 17.
1.10.4 Gene editing Process
One, single cell cloning operation step of AAVS1 gene knock-in
(1) Electric transfer program:
preparation of donor cells: human pluripotent stem cells.
The instrument comprises the following steps: an electrotransformation instrument.
Culture medium: BioCISO.
Induction of plasmid: cas9D10A, sgRNA clone AAVS1-1, sgRNA clone AAVS1-2, AAVS1 neo Vector I and AAVS1 neo Vector II.
Note: induction plasmid used for the knock-in of the eGSH gene: cas9D10A, sgRNA clone eGSH-1, sgRNA clone eGSH-2, eGSH-neo/eGSH-puro (donor) the donor plasmid here differs from AAVS1 only in the right and left recombination arms, as are the other elements. Since the gene editing process of eGSH is the same as that of AAVS1, the following description will not be repeated.
(2) The transformed human pluripotent stem cells are screened in a double antibiotic medium containing G418 and puro.
(3) And (4) carrying out single cell clone screening and culture to obtain a single cell clone strain.
Second, AAVS1 gene knock-in single cell clone strain culture reagent
(1) Culture medium: BioCISO + 300. mu.g/mL G418+ 0.5. mu.g/mL puro (should be placed at room temperature in advance, protected from light for 30-60 minutes until room temperature is restored. Note that BioCISO should not be placed at 37 ℃ for preheating to avoid reduction of the activity of the biomolecule.).
(2) Matrix glue: hESC grade Matrigel (the Matrigel working solution is added into a cell culture bottle dish and shaken up before the cells are passaged or revived to ensure that the Matrigel completely sinks to the bottom of the culture bottle dish, and any Matrigel cannot be dried at any position before the cells are used. in order to ensure that the cells can be attached to the culture bottle dish and survive better, the Matrigel is put into a 37 ℃ culture box for the time of 1:100X Matrigel cannot be less than 0.5 hour, and 1:200X Matrigel cannot be less than 2 hours).
(3) Digestion solution: EDTA was dissolved using DPBS to a final concentration of 0.5mM, pH7.4 (note: EDTA cannot be diluted with water, otherwise the cells die due to reduced osmotic pressure).
(4) Freezing and storing liquid: 60% BioCISO + 30% ESCs grade FBS + 10% DMSO (frozen stock solution is preferably ready to use).
Thirdly, the conventional maintenance subculture process
(1) Optimal time of passage and passage ratio
a. The best passage time: the overall confluency of the cells reaches 80 to 90 percent;
b. the optimal ratio of passage: the optimal confluence degree of the passage is maintained at 20-30% in the next day after passage of 1: 4-1: 7.
(2) Passage process
a. The Matrigel in the coated cell culture flask dishes was previously aspirated away, and an appropriate amount of medium (BioCISO + 300. mu.g/mL G418+ 0.5. mu.g/mL puro) was added to the flask and placed at 37 ℃ in 5% CO2Incubation in an incubator;
b. when the cells meet the requirement of passage, sucking the supernatant of the culture medium, and adding a proper amount of 0.5mM EDTA digestive solution into a cell bottle dish;
c. the cells were incubated at 37 ℃ with 5% CO2Incubating in an incubator for 5-10 minutes (digesting until most cells are observed to shrink and become round under a microscope but not float, gently blowing the cells to separate the cells from the wall, sucking the cell suspension into a centrifugal tube, and centrifuging for 5 minutes at 200 g;
d. centrifuging, discarding the supernatant, suspending the cells by using a culture medium, gently and repeatedly blowing the cells for several times until the cells are uniformly mixed, and then transferring the cells to a bottle dish prepared for coating Matrigel in advance;
e. after the cells were transferred to the cell flask, the cells were horizontally shaken up all around, observed under a mirror to be free from abnormality, and then shaken up and placed at 37 ℃ with 5% CO2Culturing in an incubator;
f. observing the adherent survival state of the cells the next day, and normally and regularly changing the culture medium every day by sucking off the culture medium.
Fourthly, freezing and storing cells
(1) According to the conventional passage operation steps, digesting the cells by using 0.5mM EDTA until most cells shrink and become round but do not float, gently blowing and beating the cells, collecting cell suspension, centrifuging for 5 minutes at 200g, removing supernatant, adding a proper amount of freezing medium to resuspend the cells, and transferring the cells to a freezing tube (suggesting that one frozen cell with 80% confluence degree of a six-well plate and 0.5 mL/cell of freezing medium is frozen);
(2) placing the freezing tube in a programmed cooling box, and immediately placing the freezing tube at-80 ℃ overnight (ensuring that the temperature of the freezing tube is reduced by 1 ℃ per minute);
(3) the next day the cells were immediately transferred into liquid nitrogen.
Fifth, cell recovery
(1) Preparing a Matrigel-coated cell bottle dish in advance, sucking out the Matrigel before recovering the cells, adding a proper amount of BioCISO into the cell bottle dish, placing at 37 ℃ and 5% CO2Incubation in an incubator;
(2) taking out the cryopreservation tube from liquid nitrogen rapidly, immediately putting the tube into a 37 ℃ water bath kettle for rapid shaking to rapidly melt cells, carefully observing, stopping shaking after ice crystals completely disappear, and transferring the cells to a biological safety cabinet;
(3) adding 10mL of DMEM/F12(1:1) basal medium into a 15mL centrifuge tube in advance, balancing to room temperature, sucking 1mL of DMEM/F12(1:1) by using a Pasteur pipette, slowly adding the DMEM/F12(1:1) into a freezing tube, gently mixing, transferring the cell suspension into a prepared 15mL centrifuge tube containing DMEM/F12(1:1), and centrifuging for 5 minutes at 200 g;
(4) carefully removing supernatant, adding appropriate amount of BioCISO, gently mixing cells, seeding into a cell bottle dish prepared in advance, horizontally shaking up and down, observing under a mirror, shaking up, and standing at 37 deg.C and 5% CO2Culturing in an incubator;
(5) the adherent survival state of the cells is observed the next day, and the liquid is normally changed on time every day. If the adherence is good, the BioCISO is changed to BioCISO + 300. mu.g/mL G418+ 0.5. mu.g/mL puro.
1.10.5 gene knock-in detection method
1. Single cell clone AAVS1 gene knock-in assay
(1) AAVS1 Gene knock-in assay
a. The purpose of the test is as follows: the cells treated by knock-in were tested for homozygote by PCR. Since the two Donor segments only have the difference in the sequences of the resistance genes, it is necessary to determine whether the cell is homozygous (the two chromosomes knock in the Donor segments of different resistance genes respectively), and it is only possible that the double-knocked-in cell is the correct homozygous by detecting whether the genome of the cell contains the Donor segments of the two resistance genes;
b. the test method comprises the steps of designing a primer in a Donor plasmid resistance gene, and designing another primer in a genome (close to a recombination arm) of an insertion site. If the Donor fragment can be correctly inserted into the genome, a target band appears, otherwise no target band appears);
c. test protocol primer sequences and PCR protocols are shown in Table 5.
TABLE 5 test protocol primer sequences and PCR protocol
The detection method of the knock-in of the second nucleic acid molecule into the 3' UTR of B2M and CIITA gene was the same as the detection principle of AAVS1, and the PCR detection conditions used were as shown in tables 6 and 7.
TABLE 6 protocol primer sequences and PCR protocol (knock-in detection of B2M site)
TABLE 7 test protocol primer sequences and PCR protocol (detection of knockin of CIITA site)
1.10.6 method for testing gene knock-in method at genome safety locus
(1) The purpose of the test is as follows: the cells treated by knock-in were tested for homozygote by PCR. Since the two Donor fragments have only difference in the sequences of the resistance genes, it is necessary to determine whether the cell is homozygous (the two chromosomes knock in the Donor fragments of different resistance genes), and it is only possible that the double-knocked-in cell is the correct homozygous by determining whether the genome of the cell contains the Donor fragments of the two resistance genes.
(2) The test method comprises the following steps: first, one primer was designed inside the Donor plasmid (non-recombinant arm portion), and then the other primer was designed on the genome (non-recombinant arm portion). If the Donor fragment is inserted correctly in the genome, the target band will appear, otherwise no target band will appear.
1.11 detection of IL-4 Ra blocking Effect of pluripotent Stem cells or derivatives thereof expressing shRNA and/or shRNA-miR targeting IL-4 Ra and exosome
Exosomes in culture supernatant after culturing and expressing pluripotent stem cells or derivatives thereof of shRNA and/or shRNA-miR of a target IL-4R alpha wrapped by exosomes are extracted by an exosome extraction kit (BestBio, lot # BB-3901). Centrifuging the culture supernatant at 4 deg.C for 15min at 3000g, collecting supernatant, centrifuging at 4 deg.C for 20min at 10000g, collecting supernatant, adding extractive solution A at a ratio of 4:1, reversing for 1min, and standing at 4 deg.C overnight. Centrifuging at 4 deg.C for 60min at 10000g, and collecting exosome precipitate. And then adding exosomes containing shRNA and/or shRNA-miR of the targeted IL-4R alpha into a culture medium for culturing the CHO cells exogenously expressing the IL-4R alpha for culturing for 48 hours, and then carrying out QPCR detection to detect the expression quantity of the IL-4R alpha.
1.12 method of treatment of allergic asthma in mice
In humanized NSG mice (The Jackson Laboratory (JAX)), human immune cells of The same donor were injected to reconstitute The immune system of The mice, and after 2 weeks, allergy of The mice induced by aluminum hydroxide gel adjuvant and chicken ovalbumin was establishedA model of sexual asthma. After the IgE of the mice is obviously increased, a treatment test is carried out, and 200uLPBS (containing human immune cells and 1X 10) is injected into tail vein6Expressing IL-4 ra-targeted shRNA and/or shRNA-miR encapsulated by exosomes or derivatives thereof) for allergic asthma treatment, wherein only the group containing human immune cells was injected as a control group. Since an increase in the level of Th2 cytokine is one of the important features of asthma, the therapeutic effect of asthma can be judged by detecting the level of Th2 cytokine (IL-4, IL-5, IL-13) and by detecting whether IgE in blood is reduced by ELISA.
1.13 methods of treatment of mouse model of atopic dermatitis
In a humanized NSG mouse (The Jackson Laboratory (JAX)), human immune cells of The same donor were injected to reconstitute The immune system of The mouse, and an atopic dermatitis model mouse generated by skin sensitization of The mouse with 2, 4-Dinitrofluorobenzene (DNFB) was established 2 weeks later. After the mice had significantly increased IgE, the treatment was tested and 200uLPBS (containing human immune cells and 1X 10 cells) was injected into the tail vein6The pluripotent stem cell derivative expressing shRNA and/or shRNA-miR targeting IL-4 ra) for atopic dermatitis treatment, wherein only the group containing human immune cells was injected as a control group.
2. Experimental protocol
The experimental scheme for knocking in shRNA and/or shRNA-miR, exosome processing synthetic gene, first nucleic acid molecule, second nucleic acid molecule, shRNA and/or miRNA processing complex-related gene, anti-interferon effector molecule, which express the target IL-4R alpha, into the genome of the pluripotent stem cell is shown in tables 8-9, wherein the "+" indicates knocking in of the gene or nucleic acid sequence and the "-" indicates knocking out of the gene.
TABLE 8 constitutive expression protocol
The plasmids selected and the specific knock-in positions were as follows:
general principle: the shRNA (or shRNA-miR) of the target IL-4R alpha is placed in a shRNA (or shRNA-miR) expression frame 2 of the corresponding plasmid, the rest shRNA (or shRNA-miR) is placed in a shRNA (or shRNA-miR) expression frame 1 of the corresponding plasmid, and the gene sequence is placed in the MCS.
B2M-3 ' UTR-miRNA-focus or CIITA-3 ' UTR-miRNA-focus, i.e. the second nucleic acid molecule (SEQ ID NO.7), knocks into the 3 ' UTR region of the B2M and CIITA genes, respectively.
The B2M/CIITA-3 'UTR-shRNA is an shRNA expression framework of a small nucleic acid molecule, namely a first nucleic acid molecule, specifically targets a transcription product of a second nucleic acid molecule in a B2M gene and a CIITA gene 3' UTR region, and a knock-in site is a genome safety site AAVS 1.
B2M/CIITA-3 'UTR-shRNA-miR is an shRNA-miR expression framework of a small nucleic acid molecule, namely a first nucleic acid molecule, a transcription product of a second nucleic acid molecule in a targeting B2M gene and CIITA gene 3' UTR region, and a knock-in site is a genome safety site AAVS 1.
CD47 represents the CD47 expression sequence, whose knock-in site is the genomic safety site AAVS 1.
If multiple fragments need to be inserted into the expression cassette or MCS, they can be ligated together using EMCV IRESWT (SEQ ID NO.99) and then inserted.
The gene knock-in sgRNA plasmid was: sgRNA clone B2M-1, sgRNA clone B2M-2, sgRNA clone CIITA-1 and sgRNA clone CIITA-2.
sgRNA plasmids used for gene knockout were: sgRNA clone B2M-3, sgRNA clone B2M-4, sgRNA clone CIITA-3 and sgRNA clone CIITA-4.
(1) Aa1 grouping
The shRNA expression frame 2 of the AAVS1KI Vector (shRNA, constitutive) plasmid was placed into the shRNA target sequence for IL-4R α.
(2) Aa2 grouping
Putting shRNA target sequences of IL-4R alpha into shRNA expression frame 2 of AAVS1KI Vector (shRNA, constitutive) plasmid, putting the rest shRNA target sequences (including target sequences of B2M/CIITA-3' UTR-shRNA) into shRNA expression frame 1, and putting MCS into gene sequences;
B2M KI Vector was put into B2M-3' UTR-miRNA-focus;
CIITA KI Vector is put into CIITA-3' UTR-miRNA-locus;
(Note: Gene knock-in (KI)) sgRNA plasmids were used as sgRNA clone B2M-1, sgRNA clone B2M-2, sgRNA clone CIITA-1, and sgRNA clone CIITA-2.
(3) Aa3 grouping
And (3) putting an shRNA target sequence of IL-4R alpha into an shRNA expression frame 2 of AAVS1KI Vector (shRNA, constitutive) plasmid, putting the rest shRNA target sequence into an shRNA expression frame 1, knocking out B2M and CIITA, and putting MCS into a gene sequence.
(Note: Knockout (KO) using sgRNA plasmids: sgRNA clone B2M-3, sgRNA clone B2M-4, sgRNA clone CIITA-3, sgRNA clone CIITA-4).
(4) Aa4 grouping:
(5) Ab1 grouping
shRNA-miR target sequence of IL-4R alpha is put into shRNA-miR expression frame 2 of AAVS1KI Vector (shRNA-miR, constitutive) plasmid.
(6) Ab2 grouping
shRNA-miR target sequences of IL-4R alpha are placed in a shRNA-miR expression frame 2 of AAVS1KI Vector (shRNA-miR, constitutive type) plasmids, the rest shRNA-miR target sequences (including target sequences of B2M/CIITA-3' UTR-shRNA-miR) are placed in a shRNA-miR expression frame 1, and gene sequences are placed in MCS;
B2M KI Vector was put into B2M-3' UTR-miRNA-focus;
placing CIITA KI Vector into CIITA-3' UTR-miRNA-locus;
(Note: knock-in (KI) sgRNA plasmids: sgRNA clone B2M-1, sgRNA clone B2M-2, sgRNA clone CIITA-1, and sgRNA clone CIITA-2 were used).
(7) Ab3 grouping
shRNA-miR target sequences of IL-4R alpha are placed in a shRNA-miR expression frame 2 of AAVS1KI Vector (shRNA-miR, constitutive) plasmid, the rest shRNA-miR target sequences are placed in a shRNA-miR expression frame 1, B2M and CIITA are knocked out, and MCS is placed in a gene sequence;
(Note: Knockout (KO) using sgRNA plasmids: sgRNA clone B2M-3, sgRNA clone B2M-4, sgRNA clone CIITA-3, sgRNA clone CIITA-4).
(8) Ab4 are grouped:
shRNA-miR sequence of targeted IL-4R alpha is put into shRNA-miR expression frame 2 of AAVS1KI Vector (shRNA-miR, constitutive type) plasmid, the rest shRNA-miR target sequence is put into shRNA-miR expression frame 1, and gene sequence is put into MCS.
When immune compatibility transformation is carried out, transformation can be carried out on hPSCs, and the derivative which is transformed into the pluripotent stem cells is used after the transformation is finished; the immune compatibility can also be modified after differentiation of hPSCs into derivatives of pluripotent stem cells.
TABLE 9 Experimental protocol for inducible expression (immuno-compatible reversible)
(1) B1 grouping:
shRNA target sequences of IL-4R alpha are put into an shRNA expression frame 2 of AAVS1KI Vector (shRNA, inducible) plasmid, the rest shRNA target sequences (including target sequences of B2M/CIITA-3' UTR-shRNA) are put into an shRNA expression frame 1, and gene sequences are put into MCS;
B2M KI Vector is put into B2M-3' UTR-miRNA-locus;
CIITA KI Vector is put into CIITA-3' UTR-miRNA-locus;
(Note: Gene knock-in (KI)) sgRNA plasmids were used as sgRNA clone B2M-1, sgRNA clone B2M-2, sgRNA clone CIITA-1, and sgRNA clone CIITA-2, and a Tet-Off system was used for induction.
(2) B2 grouping:
shRNA-miR target sequences of IL-4R alpha are placed in a shRNA-miR expression frame 2 of AAVS1KI Vector (shRNA-miR, inducible) plasmid, the rest shRNA-miR target sequences (including target sequences of B2M/CIITA-3' UTR-shRNA-miR) are placed in a shRNA-miR expression frame 1, and gene sequences are placed in MCS;
B2M KI Vector was put into B2M-3' UTR-miRNA-focus;
placing CIITA KI Vector into CIITA-3' UTR-miRNA-locus;
(Note: knock-in (KI)) sgRNA plasmids were used: sgRNA clone B2M-1, sgRNA clone B2M-2, sgRNA clone CIITA-1, and sgRNA clone CIITA-2, and a Tet-Off system was used for induction.
(3) B3 grouping:
(4) B4 grouping:
shRNA-miR expression frame 2 of AAVS1KI Vector (shRNA-miR, inducible) plasmid is placed into a shRNA-miR sequence of a target IL-4R alpha, shRNA-miR expression frame 1 is placed into the rest shRNA-miR target sequences (including target sequences of B2M/CIITA-3' UTR-shRNA-miR), and MCS is placed into a gene sequence. Adding a Tet-Off system induction system.
When immune compatibility transformation is carried out, transformation can be carried out on hPSCs, and the derivative which is transformed into the pluripotent stem cells is used after the transformation is finished; the immune compatibility can also be modified after differentiation of hPSCs into derivatives of pluripotent stem cells.
The Tet-Off system in the invention specifically comprises the following steps:
in the absence of tetracycline, the tTA protein continues to act on the tet promoter, resulting in sustained gene expression. This system is very useful in situations where it is desirable to maintain the transgene in a sustained expression state. When tetracycline is added, the tetracycline can change the structure of the tTA protein, so that the tTA protein cannot be combined with a promoter, and the expression level of a gene driven by the tTA protein is reduced. To keep the system in an "off" state, the tetracycline must be added continuously.
The sequence of the Tet-Off system and one or more immune compatible molecules is knocked into a genome safety site of the pluripotent stem cell, and the expression of the immune compatible molecules is accurately turned on or Off through the addition of tetracycline, so that the expression of major histocompatibility complex related genes in the pluripotent stem cell or the derivative thereof can be reversibly regulated and controlled.
3. Results of the experiment
3.1 detection of blocking Effect of exosomes loaded with target shRNA and/or shRNA-miR of IL-4R alpha expressed by pluripotent stem cells or derivatives thereof on IL-4R alpha
The experimental group schemes in tables 8-9 are knocked into genome safe sites of iPSCs, MSCs, NSCs and EBs cells at 37 ℃ and 0.5 percent CO2Culturing in an incubator, collecting culture medium supernatant, and extracting and culturing exosomes in the culture supernatant after expressing the exosome-encapsulated shRNA and/or shRNA-miR-targeted pluripotent stem cells and derivatives thereof by using an exosome extraction kit (BestBio, lot # BB-3901). Centrifuging the culture supernatant at 4 deg.C for 15min at 3000g, collecting supernatant, centrifuging at 4 deg.C for 20min at 10000g, collecting supernatant, adding extractive solution A at a ratio of 4:1, reversing for 1min, and standing at 4 deg.C overnight. Centrifuging at 4 deg.C for 60min at 10000g, and collecting exosome precipitate. And then adding exosome containing shRNA and/or shRNA-miR of the targeted IL-4R alpha into a culture medium for culturing the CHO cell exogenously expressing the IL-4R alpha to culture for 48h, and then carrying out QPCR detection to detect the expression quantity of the IL-4R alpha. The results of the tests of the respective experimental groups are shown in Table 10. The N (control) group refers to CHO cells expressing IL-4R alpha cultured without addition of exosomes containing shRNA and/or shRNA-miR targeting IL-4R alpha.
TABLE 10 inhibitory Effect of IL-4R alpha expression-targeting shRNA and/or shRNA-miR expressed in each experimental group on IL-4R alpha expression
As can be seen from the above table, the shRNA and/or shRNA-miR of the target IL-4R alpha, which is encapsulated by the exosome and expressed by the pluripotent stem cell or the derivative thereof, can effectively inhibit the IL-4R alpha expression of the target cell, thereby achieving the effect of blocking the IL-4R alpha. And the inhibition degree is relatively constant in each group, so that the shRNA and/or shRNA-miR of the target IL-4R alpha expressed by the pluripotent stem cell derivative is not influenced by cell differentiation morphology and other exogenous genes (immune compatibility modification).
3.2 application of shRNA and/or shRNA-miR of targeting IL-4R alpha in treatment of allergic asthma
We selected cells that only expressed shRNA and/or shRNA-miR protocols targeting IL-4 ra (Aa1), i.e., experimental groups, for testing. In a humanized NSG mouse allergic asthma model, hPSCs and hPSCs source derivatives (hPSCs-MSCs, hPSCs-NSCs and hPSCs-EBs) capable of expressing shRNA targeting IL-4R alpha are injected into the mouse, the IL-4R alpha level in blood and the cytokine level in bronchoalveolar lavage fluid are detected, and the effect of allergic asthma treatment is observed. The results of the respective experimental groups are shown in tables 11 and 12.
Note that in order to avoid the problem of immune compatibility, the immunocytes and hPSCs derived derivatives are derived from the same person.
TABLE 11 therapeutic effect (IgE content in blood) of IL-4R alpha-targeting shRNA and/or shRNA-miR expressed in each experimental group on allergic asthma
Note: the N (control) group refers to the NSG mouse model of allergic asthma without injection of experimental cells. Independent samples were tested for T (/ p < 0.01).
TABLE 12 therapeutic Effect (cytokine level in bronchoalveolar lavage fluid) of IL-4 Ra-targeting shRNA and/or shRNA-miR-expressing pluripotent stem cells or derivatives thereof expressed in each experimental group on allergic asthma
Note: denotes: there was a very significant difference compared to the control (. p < 0.01); the N (control) group refers to the NSG mouse model of allergic asthma without injection of experimental cells.
Through the experiment, the shRNA and/or shRNA-miR of the target IL-4R alpha, which is wrapped by the exosome and expressed by the prepared pluripotent stem cell or the derivative thereof can be proved to be capable of effectively inhibiting the expression of the IL-4R alpha, reducing IgE in the blood of allergic asthma mice, and simultaneously reducing the levels of Th2 cytokines (IL-4, IL-5 and IL-13), thereby achieving the effect of treating the allergic asthma.
3.3 application of shRNA and/or shRNA-miR of targeting IL-4R alpha in atopic dermatitis treatment
We selected cells that only expressed shRNA and/or shRNA-miR protocols targeting IL-4 ra (Aa1) for testing. In a humanized NSG mouse atopic dermatitis model, hPSCs and hPSCs-derived derivatives (hPSCs-MSCs, hPSCs-NSCs and hPSCs-EBs) capable of expressing shRNA targeting IL-4R alpha are injected, IgE levels in blood are detected, and the effect of atopic dermatitis treatment is observed. The results of each experimental group are shown in table 13.
TABLE 13 therapeutic Effect (IgE content in blood) of IL-4 Ra-Targeted shRNA and/or shRNA-miR-expressed in each experimental group on atopic dermatitis
Note: represents: there was a very significant difference compared to the control (. p < 0.01); the N (control) group refers to the NSG mouse model of atopic dermatitis without injection of experimental cells.
3.4 reversible expression assay for immune-compatible molecule-inducible expression sets
Through the embodiment, the hPSCs and hPSCs derived derivatives expressing shRNA and/or shRNA-miR targeting IL-4R alpha can effectively block IL-4R alpha and play roles in resisting allergy, atopic dermatitis and asthma. We must also consider the problem of immune compatibility of hPSCs and derivatives of hPSCs origin. Therefore we chose a suitable combination to test for immune compatibility.
According to the characteristic of low immunogenicity of the MSCs, in a humanized NSG mouse disease (allergic asthma) model, the hPSCs which can express shRNA/shRNA-miR of a target IL-4R alpha are injected into the humanized NSG mouse disease (allergic asthma) model to form immune compatible MSCs, the level of a cytokine (IL-13) in bronchoalveolar lavage fluid is detected, and the effect of treating the allergic asthma is observed. Note that the immunocytes used were derived from a non-identical human as the hPSCs-derived MSCs.
The control group refers to the NSG mouse disease model without MSCs cell injection.
The process of adding the Dox group is: mice were fed with 0.5mg/mL Dox added to their diets and used from the time of injection of cells expressing shRNA/shRNA-miR targeting IL-4R α until the end of the experiment. The results are shown in Table 14.
TABLE 14 reversible expression test results for immune-compatible molecule-inducible expression sets
The above experiments show that: MSCs that express only shRNA targeting IL-4 ra (group 2) have low immunogenicity and can exist for a certain time in xenobiotics, so they can exert a certain therapeutic effect on allergic asthma, whereas those that are subject to immune-compatible engineering (groups 3-7, including constitutive and reversible inducible immune-compatibility) have a better immune-compatible effect and are longer in vivo (or can coexist for a long time) than MSCs that are not subject to immune-compatible engineering, and they exert a better therapeutic effect on allergic asthma, whereas group 4 is a B2M and CIITA gene knock-out group, which completely eliminates the influence of H LA-I and HLA-II molecules, and thus their therapeutic effect on allergic asthma is optimal. However, there are groups 6-9 protocol settings because of their constitutive immune compatible modifications (knock-in/knock-out) and their inability to clear when a graft becomes mutated or otherwise undesirable. In groups 8 and 9, while injection of cells expressing shRNA targeting IL-4 ra into mice was performed, and Dox inducer (always used) was applied to the mice, the immune compatibility effect of the mice injected with cells expressing shRNA targeting IL-4 ra was abolished, and the cells existed in vivo for a period of time comparable to that of MSCs without immune compatibility modification, and the therapeutic effect of allergic asthma was comparable to that of MSCs without immune compatibility modification.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
SEQUENCE LISTING
<110> future Chile regenerative medicine institute (Guangzhou) Co., Ltd
Wang Linli
<120> pluripotent stem cell for expressing shRNA and/or shRNA-miR of targeted IL-4R alpha
<130>
<160> 103
<170> PatentIn version 3.5
<210> 1
<211> 21
<212> DNA
<213> Caenorhabditis elegans
<400> 1
ttgtactaca caaaagtact g 21
<210> 2
<211> 315
<212> DNA
<213> Artificial sequence
<400> 2
ccactcccta tcagtgatag agaaaagtga aagtcgagtt taccactccc tatcagtgat 60
agagaaaagt gaaagtcgag tttaccactc cctatcagtg atagagaaaa gtgaaagtcg 120
agtttaccac tccctatcag tgatagagaa aagtgaaagt cgagctcggt acccgggtcg 180
aggtaggcgt gtacggtggg aggcctatat aagcagagct cgtttagtga accgtcagat 240
cgcctggaga cgccatccac gctgttttga cctccataga agacaccggg accgatccag 300
cctgctagcg ccacc 315
<210> 3
<211> 9
<212> DNA
<213> Artificial sequence
<400> 3
ttcaagaga 9
<210> 4
<211> 119
<212> DNA
<213> Artificial sequence
<400> 4
gaggcttcag tactttacag aatcgttgcc tgcacatctt ggaaacactt gctgggatta 60
cttcttcagg ttaacccaac agaaggctaa agaaggtata ttgctgttga cagtgagcg 119
<210> 5
<211> 19
<212> DNA
<213> Artificial sequence
<400> 5
tagtgaagcc acagatgta 19
<210> 6
<211> 119
<212> DNA
<213> Artificial sequence
<400> 6
tgcctactgc ctcggacttc aaggggctac tttaggagca attatcttgt ttactaaaac 60
tgaatacctt gctatctctt tgatacattt ttacaaagct gaattaaaat ggtataaat 119
<210> 7
<211> 210
<212> DNA
<213> Artificial sequence
<400> 7
attctagata cagtactttt gtgtagtaca acgtacagta cttttgtgta gtacaacgta 60
cagtactttt gtgtagtaca acgtacagta cttttgtgta gtacaacgta cagtactttt 120
gtgtagtaca acgtacagta cttttgtgta gtacaacgta cagtactttt gtgtagtaca 180
acgtacagta cttttgtgta gtacaacgta 210
<210> 8
<211> 21
<212> DNA
<213> human
<400> 8
gggagcagag aattctctta t 21
<210> 9
<211> 21
<212> DNA
<213> human
<400> 9
ggagcagaga attctcttat c 21
<210> 10
<211> 21
<212> DNA
<213> human
<400> 10
gagcagagaa ttctcttatc c 21
<210> 11
<211> 21
<212> DNA
<213> human
<400> 11
gctacctgga gcttcttaac a 21
<210> 12
<211> 21
<212> DNA
<213> human
<400> 12
ggagcttctt aacagcgatg c 21
<210> 13
<211> 21
<212> DNA
<213> human
<400> 13
gggtctccag tatattcatc t 21
<210> 14
<211> 21
<212> DNA
<213> human
<400> 14
gctcccactc catgaggtat t 21
<210> 15
<211> 21
<212> DNA
<213> human
<400> 15
ggtatttctt cacatccgtg t 21
<210> 16
<211> 21
<212> DNA
<213> human
<400> 16
aggagacacg gaatgtgaag g 21
<210> 17
<211> 21
<212> DNA
<213> human
<400> 17
gctcccactc catgaggtat t 21
<210> 18
<211> 21
<212> DNA
<213> human
<400> 18
ggtatttcta cacctccgtg t 21
<210> 19
<211> 21
<212> DNA
<213> human
<400> 19
ggaccggaac acacagatct a 21
<210> 20
<211> 21
<212> DNA
<213> human
<400> 20
ttcttacttc cctaatgaag t 21
<210> 21
<211> 21
<212> DNA
<213> human
<400> 21
aagttaagaa cctgaatata a 21
<210> 22
<211> 21
<212> DNA
<213> human
<400> 22
aacctgaata taaatttgtg t 21
<210> 23
<211> 21
<212> DNA
<213> human
<400> 23
gggtctggtg ggcatcatta t 21
<210> 24
<211> 21
<212> DNA
<213> human
<400> 24
ggtctggtgg gcatcattat t 21
<210> 25
<211> 21
<212> DNA
<213> human
<400> 25
gcatcattat tgggaccatc t 21
<210> 26
<211> 21
<212> DNA
<213> human
<400> 26
gatgaccaca ttcaaggaag a 21
<210> 27
<211> 21
<212> DNA
<213> human
<400> 27
gaccacattc aaggaagaac t 21
<210> 28
<211> 21
<212> DNA
<213> human
<400> 28
gctttcctgc ttggcagtta t 21
<210> 29
<211> 21
<212> DNA
<213> human
<400> 29
gcgtaagtct gagtgtcatt t 21
<210> 30
<211> 21
<212> DNA
<213> human
<400> 30
gacaatttaa ggaagaatct t 21
<210> 31
<211> 21
<212> DNA
<213> human
<400> 31
ggccatagtt ctccctgatt g 21
<210> 32
<211> 21
<212> DNA
<213> human
<400> 32
gccatagttc tccctgattg a 21
<210> 33
<211> 21
<212> DNA
<213> human
<400> 33
gcagatgacc acattcaagg a 21
<210> 34
<211> 21
<212> DNA
<213> human
<400> 34
gcagcaggat aagtatgagt g 21
<210> 35
<211> 21
<212> DNA
<213> human
<400> 35
gcaggataag tatgagtgtc a 21
<210> 36
<211> 21
<212> DNA
<213> human
<400> 36
ggttcctgca cagagacatc t 21
<210> 37
<211> 21
<212> DNA
<213> human
<400> 37
ggatgtggaa cccacagata c 21
<210> 38
<211> 21
<212> DNA
<213> human
<400> 38
gatgtggaac ccacagatac a 21
<210> 39
<211> 21
<212> DNA
<213> human
<400> 39
gtggaaccca cagatacaga g 21
<210> 40
<211> 21
<212> DNA
<213> human
<400> 40
gggtagcaac tgtcaccttg a 21
<210> 41
<211> 21
<212> DNA
<213> human
<400> 41
ggatttcgtg ttccagttta a 21
<210> 42
<211> 21
<212> DNA
<213> human
<400> 42
gcatgtgcta cttcaccaac g 21
<210> 43
<211> 21
<212> DNA
<213> human
<400> 43
gctcacagtc atcaattata g 21
<210> 44
<211> 21
<212> DNA
<213> human
<400> 44
gccctgaaga cagaatgttc c 21
<210> 45
<211> 21
<212> DNA
<213> human
<400> 45
gcggaccatg tgtcaactta t 21
<210> 46
<211> 21
<212> DNA
<213> human
<400> 46
gcctgatagg acccatattc c 21
<210> 47
<211> 21
<212> DNA
<213> human
<400> 47
gcatccaata gacgtcattt g 21
<210> 48
<211> 21
<212> DNA
<213> human
<400> 48
gcgtcactgg cacagatata a 21
<210> 49
<211> 21
<212> DNA
<213> human
<400> 49
ggatggattt gattatgatc c 21
<210> 50
<211> 21
<212> DNA
<213> human
<400> 50
ggaccttgga acaatggatt g 21
<210> 51
<211> 21
<212> DNA
<213> human
<400> 51
gctaattctt gctgaacttc t 21
<210> 52
<211> 21
<212> DNA
<213> human
<400> 52
gcagttctgt tgccactctc t 21
<210> 53
<211> 21
<212> DNA
<213> human
<400> 53
gggagagttc atccaggaaa t 21
<210> 54
<211> 21
<212> DNA
<213> human
<400> 54
ggagagttca tccaggaaat t 21
<210> 55
<211> 21
<212> DNA
<213> human
<400> 55
gggttggttt atccaggaat a 21
<210> 56
<211> 21
<212> DNA
<213> human
<400> 56
ggatcagaag agaagccaac g 21
<210> 57
<211> 21
<212> DNA
<213> human
<400> 57
ggttcaccat ccaggtgttc a 21
<210> 58
<211> 21
<212> DNA
<213> human
<400> 58
ggaggaactt tgtgaacatt c 21
<210> 59
<211> 21
<212> DNA
<213> human
<400> 59
gctgtaagaa ggatgctttc a 21
<210> 60
<211> 21
<212> DNA
<213> human
<400> 60
gctgcaggca ggattgtttc a 21
<210> 61
<211> 19
<212> DNA
<213> human
<400> 61
gcctcgagtt tgagagcta 19
<210> 62
<211> 19
<212> DNA
<213> human
<400> 62
agacattctg gatgagtta 19
<210> 63
<211> 19
<212> DNA
<213> human
<400> 63
gggtctgtta cccaaagaa 19
<210> 64
<211> 21
<212> DNA
<213> human
<400> 64
ggacactggt tcaacacctg t 21
<210> 65
<211> 21
<212> DNA
<213> human
<400> 65
ggttcaacac ctgtgacttc a 21
<210> 66
<211> 21
<212> DNA
<213> human
<400> 66
acctgtgact tcatgtgtgc g 21
<210> 67
<211> 253
<212> DNA
<213> Artificial sequence
<400> 67
gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgttagagag 60
ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 120
aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat 180
atgcttaccg taacttgaaa gtatttcgat ttcttggctt tatatatctt gtggaaagga 240
cgctagcgcc acc 253
<210> 68
<211> 686
<212> DNA
<213> Artificial sequence
<400> 68
gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc tgttagagag 60
ataattggaa ttaatttgac tgtaaacaca aagatattag tacaaaatac gtgacgtaga 120
aagtaataat ttcttgggta gtttgcagtt ttaaaattat gttttaaaat ggactatcat 180
atgcttaccg taacttgaaa gtatttcgat ttcttggctt tatatatctt gtggaaagga 240
ctttaccact ccctatcagt gatagagaaa agtgaaagtc gagtttacca ctccctatca 300
gtgatagaga aaagtgaaag tcgagtttac cactccctat cagtgataga gaaaagtgaa 360
agtcgagttt accactccct atcagtgata gagaaaagtg aaagtcgagt ttaccactcc 420
ctatcagtga tagagaaaag tgaaagtcga gtttaccact ccctatcagt gatagagaaa 480
agtgaaagtc gagtttacca ctccctatca gtgatagaga aaagtgaaag tcgagctcgg 540
tacccgggtc gaggtaggcg tgtacggtgg gaggcctata taagcagagc tcgtttagtg 600
aaccgtcaga tcgcctggag acgccatcca cgctgttttg acctccatag aagacaccgg 660
gaccgatcca gcctgctagc gccacc 686
<210> 69
<211> 1607
<212> DNA
<213> human
<400> 69
atgaatactc tccctgaaca ttcatgtgac gtgttgatta tcggtagcgg cgcagccgga 60
ctttcactgg cgctacgcct ggctgaccag catcaggtca tcgttctaag taaggccggt 120
aacgaggttc aacattttat gcccagggcg gtattgccgc cgtgtttgat aaactgacag 180
cattgactcg catgtggaag acacattgat tgccggggct ggtatttgcg atcgccatgc 240
agttgaattt gtcgccagca atgcacgatc ctgtgtgcaa tggctaatcg accagggggt 300
gttgtttgat acccacattc aaccgaatgg cgaagaaagt taccatctga cccgtgaagg 360
tggacatagt caccgtcgta ttcttcatgc cgccgacgcc accggtagag aagtagaaac 420
cacgctggtg agcaaggcgc tgaaccatcc gaatattcgc gtgctggagc gcagcaacgc 480
ggttgatctg attgtttctg acaaaattgg cctgccgggc acgcgacggg ttgttggcgc 540
gtgggtatgg aaccgtaata aagaaacggt ggaaacctgc cacgcaaaag cggtggtgct 600
ggcaaccggc ggtgcgtcga aggtttatca gtacaccacc aatccggata tttcttctgg 660
cgatggcatt gctatggcgt ggcgcgcagg ctgccggttg ccaatctcga tttaatcagt 720
tccaccctac cgcgctatat cacccacagg cacgcaattt cctgttaaca gaagcactgc 780
gcggcgaggc gcttatctca agcgcccgga tggtacgcgt ttatccgatt ttgatgagcg 840
cggcgaactg ccccgcgcga tattgtcgcc cgcgccattg accatgaaat gaaacgcctc 900
ggcgcagatt gtatgttcct tgatatcagc cataagcccg ccgattttat tcgccagcat 960
ttcccgatga tttatgaaaa gctgctcggg ctgggattga tctcacacaa gaaccggtac 1020
cgattgtgcc tgctgcacat tatacctgcg gtggtgtaat ggttgatgat catgggcgta 1080
cggacgtcga gggcttgtat gccattggcg aggtgagtta taccggctta cacggcgcta 1140
accgcatggc ctcgaattca ttgctggagt gtctggtcta tggctggtcg gcggcggaag 1200
atatcaccag acgtatgcct tatgcccacg acatcagtac gttaccgccg tgggatgaaa 1260
gccgcgttga gaaccctgac gaacggtagt aattcagcat aactggcacg agctacgtct 1320
gtttatgtgg gattacgttg gcattgtgcg cacaacgaag cgcctggaac gcgccctgcg 1380
gcggataacc atgctccaac aagaaataga cgaatattac gcccatttcc gcgtctcaaa 1440
taatttgctg gagctgcgta atctggtaca ggttgccgag ttgattgttc gctgtgcaat 1500
gatgcgtaaa gagagtcggg gttgcatttc acgctggatt atccggaact gctcacccat 1560
tccggtccgt cgatccttcc cccggcaatc attacataaa cagataa 1607
<210> 70
<211> 411
<212> DNA
<213> human
<400> 70
ggaagtggtg ccggcaccgg cggcatgtac gtgcgcttcg aggtgcccga ggacatgcag 60
aacgaggccc tgagcctgct ggaaaaagtg cgcgagagcg gcaaagtgaa gaagggcacc 120
aacgaaacca ccaaggccgt ggaacggggc ctggccaagc tggtgtatat cgccgaggac 180
gtggaccccc ccgagattgt ggcccatctg cccctgctgt gcgaagagaa gaacgtgccc 240
tacatctacg tgaagtccaa gaacgacctg ggcagagccg tgggcatcga ggtgccatgt 300
gcctctgccg ccatcatcaa cgagggcgag ctgcggaaag aactgggcag cctggtggaa 360
aagatcaagg gcctgcagaa gggttccggt ggatccggtt ccggacgggc t 411
<210> 71
<211> 23
<212> DNA
<213> Artificial sequence
<400> 71
tataaggtgg tcccagctcg ggg 23
<210> 72
<211> 23
<212> DNA
<213> Artificial sequence
<400> 72
agggccggtt aatgtggctc tgg 23
<210> 73
<211> 23
<212> DNA
<213> Artificial sequence
<400> 73
ctcctgttat attctagaac agg 23
<210> 74
<211> 23
<212> DNA
<213> Artificial sequence
<400> 74
tttcagcatc aatgtaccct ggg 23
<210> 75
<211> 20
<212> DNA
<213> Artificial sequence
<400> 75
cgcgagcaca gctaaggcca 20
<210> 76
<211> 20
<212> DNA
<213> Artificial sequence
<400> 76
actctctctt tctggcctgg 20
<210> 77
<211> 23
<212> DNA
<213> Artificial sequence
<400> 77
ggcactcaga agacactgat ggg 23
<210> 78
<211> 23
<212> DNA
<213> Artificial sequence
<400> 78
aaggtgtctg gtcggagagc agg 23
<210> 79
<211> 20
<212> DNA
<213> Artificial sequence
<400> 79
acccagcagg gcgtggagcc 20
<210> 80
<211> 20
<212> DNA
<213> Artificial sequence
<400> 80
gtcagagccc caaggtaaaa 20
<210> 81
<211> 804
<212> DNA
<213> Artificial sequence
<400> 81
tgctttctct gacctgcatt ctctcccctg ggcctgtgcc gctttctgtc tgcagcttgt 60
ggcctgggtc acctctacgg ctggcccaga tccttccctg ccgcctcctt caggttccgt 120
cttcctccac tccctcttcc ccttgctctc tgctgtgttg ctgcccaagg atgctctttc 180
cggagcactt ccttctcggc gctgcaccac gtgatgtcct ctgagcggat cctccccgtg 240
tctgggtcct ctccgggcat ctctcctccc tcacccaacc ccatgccgtc ttcactcgct 300
gggttccctt ttccttctcc ttctggggcc tgtgccatct ctcgtttctt aggatggcct 360
tctccgacgg atgtctccct tgcgtcccgc ctccccttct tgtaggcctg catcatcacc 420
gtttttctgg acaaccccaa agtaccccgt ctccctggct ttagccacct ctccatcctc 480
ttgctttctt tgcctggaca ccccgttctc ctgtggattc gggtcacctc tcactccttt 540
catttgggca gctcccctac cccccttacc tctctagtct gtgctagctc ttccagcccc 600
ctgtcatggc atcttccagg ggtccgagag ctcagctagt cttcttcctc caacccgggc 660
ccctatgtcc acttcaggac agcatgtttg ctgcctccag ggatcctgtg tccccgagct 720
gggaccacct tatattccca gggccggtta atgtggctct ggttctgggt acttttatct 780
gtcccctcca ccccacagtg gggc 804
<210> 82
<211> 837
<212> DNA
<213> Artificial sequence
<400> 82
actagggaca ggattggtga cagaaaagcc ccatccttag gcctcctcct tcctagtctc 60
ctgatattgg gtctaacccc cacctcctgt taggcagatt ccttatctgg tgacacaccc 120
ccatttcctg gagccatctc tctccttgcc agaacctcta aggtttgctt acgatggagc 180
cagagaggat cctgggaggg agagcttggc agggggtggg agggaagggg gggatgcgtg 240
acctgcccgg ttctcagtgg ccaccctgcg ctaccctctc ccagaacctg agctgctctg 300
acgcggccgt ctggtgcgtt tcactgatcc tggtgctgca gcttccttac acttcccaag 360
aggagaagca gtttggaaaa acaaaatcag aataagttgg tcctgagttc taactttggc 420
tcttcacctt tctagtcccc aatttatatt gttcctccgt gcgtcagttt tacctgtgag 480
ataaggccag tagccagccc cgtcctggca gggctgtggt gaggaggggg gtgtccgtgt 540
ggaaaactcc ctttgtgaga atggtgcgtc ctaggtgttc accaggtcgt ggccgcctct 600
actccctttc tctttctcca tccttctttc cttaaagagt ccccagtgct atctgggaca 660
tattcctccg cccagagcag ggtcccgctt ccctaaggcc ctgctctggg cttctgggtt 720
tgagtccttg gcaagcccag gagaggcgct caggcttccc tgtccccctt cctcgtccac 780
catctcatgc ccctggctct cctgcccctt ccctacaggg gttcctggct ctgctct 837
<210> 83
<211> 900
<212> DNA
<213> Artificial sequence
<400> 83
cctggacttc tccagtactt tctggctgga ttggtatctg aggctagtag gaagggcttg 60
ttcctgctgg gtagctctaa acaatgtatt catgggtagg aacagcagcc tattctgcca 120
gccttatttc taaccatttt agacatttgt tagtacatgg tattttaaaa gtaaaactta 180
atgtcttcct tttttttctc cactgtcttt ttcatagatc gagacatgta agcagcatca 240
tggaggtaag tttttgacct tgagaaaatg tttttgtttc actgtcctga ggactattta 300
tagacagctc taacatgata accctcacta tgtggagaac attgacagag taacatttta 360
gcagggaaag aagaatccta cagggtcatg ttcccttctc ctgtggagtg gcatgaagaa 420
ggtgtatggc cccaggtatg gccatattac tgaccctcta cagagagggc aaaggaactg 480
ccagtatggt attgcaggat aaaggcaggt ggttacccac attacctgca aggctttgat 540
ctttcttctg ccatttccac attggacatc tctgctgagg agagaaaatg aaccactctt 600
ttcctttgta taatgttgtt ttattcttca gacagaagag aggagttata cagctctgca 660
gacatcccat tcctgtatgg ggactgtgtt tgcctcttag aggttcccag gccactagag 720
gagataaagg gaaacagatt gttataactt gatataatga tactataata gatgtaacta 780
caaggagctc cagaagcaag agagagggag gaacttggac ttctctgcat ctttagttgg 840
agtccaaagg cttttcaatg aaattctact gcccagggta cattgatgct gaaaccccat 900
<210> 84
<211> 900
<212> DNA
<213> Artificial sequence
<400> 84
tcaaatctcc tgttatattc tagaacaggg aattgatttg ggagagcatc aggaaggtgg 60
atgatctgcc cagtcacact gttagtaaat tgtagagcca ggacctgaac tctaatatag 120
tcatgtgtta cttaatgacg gggacatgtt ctgagaaatg cttacacaaa cctaggtgtt 180
gtagcctact acacgcatag gctacatggt atagcctatt gctcctagac tacaaacctg 240
tacagcctgt tactgtactg aatactgtgg gcagttgtaa cacaatggta agtatttgtg 300
tatctaaaca tagaagttgc agtaaaaata tgctatttta atcttatgag accactgtca 360
tatatacagt ccatcattga ccaaaacatc atatcagcat tttttcttct aagattttgg 420
gagcaccaaa gggatacact aacaggatat actctttata atgggtttgg agaactgtct 480
gcagctactt cttttaaaaa ggtgatctac acagtagaaa ttagacaagt ttggtaatga 540
gatctgcaat ccaaataaaa taaattcatt gctaaccttt ttcttttctt ttcaggtttg 600
aagatgccgc atttggattg gatgaattcc aaattctgct tgcttgcttt ttaatattga 660
tatgcttata cacttacact ttatgcacaa aatgtagggt tataataatg ttaacatgga 720
catgatcttc tttataattc tactttgagt gctgtctcca tgtttgatgt atctgagcag 780
gttgctccac aggtagctct aggagggctg gcaacttaga ggtggggagc agagaattct 840
cttatccaac atcaacatct tggtcagatt tgaactcttc aatctcttgc actcaaagct 900
<210> 85
<211> 900
<212> DNA
<213> Artificial sequence
<400> 85
cttgacaagt ctcctgctcc tcactatgaa gatcactgtc ccccagccct gtgctccccg 60
cactgtgctg cacgtccacc tccattccac tgcccctccc atccccccat cttgatagca 120
cccttcccag gtgtcaagct gcccctccta gagtgtcctg cctaaacccc ctctcctggc 180
tcctcccgct acagcatgtt ctctgaggac actaaccacg ctggaccttg aactgggtac 240
ttgtggacac agctcttctc caggctgtat cccatgagcc tcagcatcct ggcacccggc 300
ccctgctggt tcagggttgg cccctgcccg gctgcggaat gaaccacatc ttgctctgct 360
gacagacaca ggcccggctc caggctcctt tagcgcccag ttgggtggat gcctggtggc 420
agctgcggtc cacccaggag ccccgaggcc ttctctgaag gacattgcgg acagccacgg 480
ccaggccaga gggagtgaca gaggcagccc cattctgcct gcccaggccc ctgccaccct 540
ggggagaaag tacttctttt tttttatttt tagacagagt ctcactgttg cccaggctgg 600
cgtgcagtgg tgcgatctgg gttcactgca acctccgcct cttgggttca agcgattctt 660
ctgcttcagc ctcccgagta gctgggacta caggcaccca ccatcatgtc tggctaattt 720
ttcattttta gtagagacag ggttttgcca tgttggccag gctggtctca aactcttgac 780
ctcaggtgat ccacccacct cagcctccca aagtgctggg attacaagcg tgagccactg 840
caccgggcca cagagaaagt acttctccac cctgctctcc gaccagacac cttgacaggg 900
<210> 86
<211> 900
<212> DNA
<213> Artificial sequence
<400> 86
cacaccgggc actcagaaga cactgatggg caacccccag cctgctaatt ccccagattg 60
caacaggctg ggcttcagtg gcagctgctt ttgtctatgg gactcaatgc actgacattg 120
ttggccaaag ccaaagctag gcctggccag atgcaccagc ccttagcagg gaaacagcta 180
atgggacact aatggggcgg tgagagggga acagactgga agcacagctt catttcctgt 240
gtcttttttc actacattat aaatgtctct ttaatgtcac aggcaggtcc agggtttgag 300
ttcataccct gttaccattt tggggtaccc actgctctgg ttatctaata tgtaacaagc 360
caccccaaat catagtggct taaaacaaca ctcacattta ttctgctcac atatctgtca 420
tttgagcagg gctcagcggg gacagctcct tctgtcctac tctgtgtcag gtggggcagc 480
ttgagggttg ggctggtgtc acctgaagac tcattcttct gtacgtctga caggcaatgc 540
tggctgttgg ctgggggcct cagtgccact acggaatagt tggctaggac ccctccatgt 600
gggctagttg ggcttcctca tagtatggtg gctgggttgg agggtgtccc aaaaagaaag 660
gaggggatag agagagacca cttttcataa cctagcctta gaagtcacac agtattactt 720
ctgctacata tatatgtttt aagaggcagg gtctcactct gtcgcccagt ctggaatgca 780
gtggtatgat cacggctcac tgcagcctca acctcctggg ctaagtgatc ctcccacctc 840
agcctcccga atagctggga ctacaggtgt gagtcaccaa gcccagttaa tctttagttt 900
<210> 87
<211> 22
<212> DNA
<213> Artificial sequence
<400> 87
ccatagctca gtctggtcta tc 22
<210> 88
<211> 22
<212> DNA
<213> Artificial sequence
<400> 88
ctcttcgtcc agatcatcct ga 22
<210> 89
<211> 22
<212> DNA
<213> Artificial sequence
<400> 89
ccatagctca gtctggtcta tc 22
<210> 90
<211> 20
<212> DNA
<213> Artificial sequence
<400> 90
cacaccttgc cgatgtcgag 20
<210> 91
<211> 24
<212> DNA
<213> Artificial sequence
<400> 91
gcactgaacg aacatctcaa gaag 24
<210> 92
<211> 22
<212> DNA
<213> Artificial sequence
<400> 92
ctcttcgtcc agatcatcct ga 22
<210> 93
<211> 24
<212> DNA
<213> Artificial sequence
<400> 93
gcactgaacg aacatctcaa gaag 24
<210> 94
<211> 20
<212> DNA
<213> Artificial sequence
<400> 94
cacaccttgc cgatgtcgag 20
<210> 95
<211> 22
<212> DNA
<213> Artificial sequence
<400> 95
tgctccgggt ttgtctcaga tg 22
<210> 96
<211> 22
<212> DNA
<213> Artificial sequence
<400> 96
ctcttcgtcc agatcatcct ga 22
<210> 97
<211> 22
<212> DNA
<213> Artificial sequence
<400> 97
tgctccgggt ttgtctcaga tg 22
<210> 98
<211> 20
<212> DNA
<213> Artificial sequence
<400> 98
cacaccttgc cgatgtcgag 20
<210> 99
<211> 590
<212> DNA
<213> Artificial sequence
<400> 99
cccctctccc tccccccccc ctaacgttac tggccgaagc cgcttggaat aaggccggtg 60
tgcgtttgtc tatatgttat tttccaccat attgccgtct tttggcaatg tgagggcccg 120
gaaacctggc cctgtcttct tgacgagcat tcctaggggt ctttcccctc tcgccaaagg 180
aatgcaaggt ctgttgaatg tcgtgaagga agcagttcct ctggaagctt cttgaagaca 240
aacaacgtct gtagcgaccc tttgcaggca gcggaacccc ccacctggcg acaggtgcct 300
ctgcggccaa aagccacgtg tataagatac acctgcaaag gcggcacaac cccagtgcca 360
cgttgtgagt tggatagttg tggaaagagt caaatggctc tcctcaagcg tattcaacaa 420
ggggctgaag gatgcccaga aggtacccca ttgtatggga tctgatctgg ggcctcggtg 480
cacatgcttt acatgtgttt agtcgaggtt aaaaaaacgt ctaggccccc cgaaccacgg 540
ggacgtggtt ttcctttgaa aaacacgatg ataatatggc cacaaccatg 590
<210> 100
<211> 24
<212> DNA
<213> Caenorhabditis elegans
<400> 100
tcacaacctc ctagaaagag taga 24
<210> 101
<211> 21
<212> DNA
<213> human
<400> 101
gggcgcgcag ataattaaag a 21
<210> 102
<211> 21
<212> DNA
<213> human
<400> 102
ggcgcgcaga taattaaaga t 21
<210> 103
<211> 21
<212> DNA
<213> human
<400> 103
gcgcgcagat aattaaagat t 21
Claims (23)
1. A pluripotent stem cell or a derivative thereof, wherein: the genome of the pluripotent stem cell or the derivative thereof is introduced with an expression sequence of shRNA and/or shRNA-miR of a target IL-4R alpha.
2. The pluripotent stem cell or the derivative thereof according to claim 1, wherein: the target sequence of the shRNA and/or shRNA-miR targeting IL-4R alpha is shown in SEQ ID NO. 101-SEQ ID NO. 103.
3. The pluripotent stem cell or derivative thereof according to claim 1, wherein: the B2M and/or CIITA gene of the pluripotent stem cell or the derivative thereof is knocked out.
4. The pluripotent stem cell or derivative thereof according to claim 1, wherein: the genome of the pluripotent stem cell or the derivative thereof is also introduced with a first nucleic acid molecule;
and the pluripotent stem cell or the derivative thereof has a second nucleic acid molecule introduced into the 3' UTR region of the immune response-associated gene; the first nucleic acid molecule encodes a small nucleic acid molecule that mediates RNA interference, which specifically targets the transcript of the second nucleic acid molecule, and which does not target any other mRNA or incrna of the pluripotent stem cell or a derivative thereof.
5. The pluripotent stem cell or the derivative thereof according to claim 4, wherein the small nucleic acid molecule comprises at least one of a short interfering nucleic acid, a short interfering RNA, a double-stranded RNA, preferably miRNA, shRNA-miR.
6. The pluripotent stem cells or derivatives thereof according to claim 5, wherein the pluripotent stem cells or derivatives thereof are derived from a human; the sequence of the small nucleic acid molecule is a random sequence of a non-human species that does not target any mRNA or incrna of a human.
7. The pluripotent stem cell or the derivative thereof according to claim 4, wherein the second nucleic acid molecule comprises the reverse complement of at least 3 repeats of the small nucleic acid molecule sequence, preferably 6-10 repeats of the small nucleic acid molecule sequence.
8. The pluripotent stem cell or derivative thereof according to claim 1, wherein: the genome of the pluripotent stem cell or the derivative thereof is further introduced with one or more immune compatible molecule expression sequences for regulating the expression of genes associated with an immune response in the pluripotent stem cell or the derivative thereof.
9. The pluripotent stem cell or the derivative thereof according to claim 4 or 8, wherein: the genes associated with the immune response include:
(1) major histocompatibility complex genes including at least one of HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DQA1, HLA-DQB1, HLA-DPA1 and HLA-DPB 1;
(2) major histocompatibility complex-associated genes including at least one of B2M and CIITA.
10. The pluripotent stem cell or the derivative thereof according to claim 8, wherein: the immune-compatible molecule includes any one or more of:
(1) immune tolerance related genes including CD47 or HLA-G;
(2) HLA-C molecules, including HLA-C multiple alleles of which the proportion in the population is over 90 percent in total, or fusion protein genes consisting of the HLA-C multiple alleles of which the proportion is over 90 percent and B2M;
(3) shRNA and/or shRNA-miR targeting major histocompatibility complex genes including at least one of HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DQA1, HLA-DQB1, HLA-DPA1 and HLA-DPB 1;
(4) shRNA and/or shRNA-miR targeting a major histocompatibility complex-associated gene that includes at least one of B2M and CIITA.
11. The pluripotent stem cell or derivative thereof of claim 10, wherein:
the target sequence of the shRNA and/or shRNA-miR targeting B2M is selected from one of SEQ ID NO. 8-SEQ ID NO. 10;
the target sequence of the shRNA and/or shRNA-miR of the targeting CIITA is selected from SEQ ID NO. 11-SEQ ID NO.
13;
the target sequence of the target HLA-A shRNA and/or shRNA-miR is selected from one of SEQ ID NO. 14-SEQ ID NO. 16;
the target sequence of the target HLA-B shRNA and/or shRNA-miR is selected from one of SEQ ID NO. 17-SEQ ID NO. 19;
the target sequence of the target HLA-C shRNA and/or shRNA-miR is selected from one of SEQ ID NO. 20-SEQ ID NO. 22;
the target sequence of the target HLA-DRA shRNA and/or shRNA-miR is selected from one of SEQ ID NO. 23-SEQ ID NO. 25;
the target sequence of the shRNA and/or shRNA-miR of the target HLA-DRB1 is selected from one of SEQ ID NO. 26-SEQ ID NO. 28;
the target sequence of the shRNA and/or shRNA-miR targeting HLA-DRB3 is selected from one of SEQ ID NO. 29-SEQ ID NO. 30;
the target sequence of the shRNA and/or shRNA-miR of the target HLA-DRB4 is selected from one of SEQ ID NO. 31-SEQ ID NO. 33;
the target sequence of the shRNA and/or shRNA-miR of the target HLA-DRB5 is selected from one of SEQ ID NO. 34-SEQ ID NO. 36;
the target sequence of the shRNA and/or shRNA-miR of the target HLA-DQA1 is selected from one of SEQ ID NO. 37-SEQ ID NO. 39;
the target sequence of the shRNA and/or shRNA-miR targeting HLA-DQB1 is selected from one of SEQ ID NO. 40-SEQ ID NO. 42;
the target sequence of the shRNA and/or shRNA-miR of the target HLA-DPA1 is selected from one of SEQ ID NO. 43-SEQ ID NO. 45;
the target sequence of the shRNA and/or shRNA-miR of the target HLA-DPB1 is selected from one of SEQ ID NO. 46-SEQ ID NO. 48.
12. The pluripotent stem cell or the derivative thereof according to any one of claims 1 to 11, wherein: shRNA and/or miRNA processing complex related genes and/or anti-interferon effector molecules are also introduced into the genome of the pluripotent stem cell or the derivative thereof.
13. The pluripotent stem cell or derivative thereof of claim 12, wherein: the shRNA and/or miRNA processing complex related gene comprises at least one of Drosha, Ago1, Ago2, Dicer1, Exportin-5, TRBP (TARBP2), PACT (PRKRA) and DGCR 8;
the anti-interferon effector molecule is shRNA and/or shRNA-miR of at least one of PKR, 2-5As, IRF-3 and IRF-7.
14. The pluripotent stem cell or the derivative thereof of claim 13, wherein:
the target sequence of the target PKR-targeting shRNA and/or shRNA-miR is selected from one of SEQ ID NO. 49-SEQ ID NO. 51;
the target sequence of the shRNA and/or shRNA-miR targeting 2-5As is selected from one of SEQ ID NO. 52-SEQ ID NO. 60;
the target sequence of the IRF-3-targeting shRNA and/or shRNA-miR is selected from one of SEQ ID NO. 61-SEQ ID NO 63;
the target sequence of the IRF-7-targeting shRNA and/or shRNA-miR is selected from one of SEQ ID No. 64-SEQ ID No. 66.
15. The pluripotent stem cell or derivative thereof of claim 2, 11 or 14, wherein: the expression framework of the shRNA and/or shRNA-miR of the target IL-4R alpha, the major histocompatibility complex gene, the major histocompatibility complex related gene, PKR, 2-5As, IRF-3 or IRF-7 is As follows:
(1) shRNA expression framework: 5 'to 3' in turn comprising the shRNA target sequence of claim 2, 11 or 14, a stem-loop sequence, the reverse complement of the shRNA target sequence of claim 2, 7 or 10, Poly T; the two reverse complementary target sequences are separated by a middle stem-loop sequence to form a hairpin structure, and finally Poly T is connected to be used as a transcription terminator of RNA polymerase III;
(2) shRNA-miR expression framework: replacing a target sequence in microRNA-30 or microRNA-155 with the shRNA-miR target sequence of claim 2, 11 or 14.
16. The pluripotent stem cell or derivative thereof of claim 15, wherein: the length of a stem-loop sequence in the shRNA expression frame is 3-9 bases; the length of the Poly T is 5-6 bases.
17. The pluripotent stem cell or derivative thereof according to claim 4, 8 or 12, wherein: an inducible gene expression system is also introduced into the genome of the pluripotent stem cell or the derivative thereof and is used for regulating and controlling the expression of the first nucleic acid molecule and/or the immune compatible molecule and/or the shRNA and/or the miRNA processing complex related gene and/or the anti-interferon effector molecule; preferably, the inducible gene expression system is at least one of a Tet-Off system and a dimer inducible expression system.
18. The pluripotent stem cell or derivative thereof according to any one of claims 1 to 17, wherein: the genome of the pluripotent stem cell or the derivative thereof is also introduced with an exosome processing synthetic gene;
preferably, the exosome processing synthetic gene comprises at least one of STEAP3, Syndevan-4, a fragment of L-aspartate oxidase (SEQ ID No.69), CD63-L7Ae (SEQ ID No.70) and Cx 43S 368A.
19. The pluripotent stem cell or derivative thereof of claim 18, wherein: the introduction of the expression sequence of the shRNA and/or shRNA-miR of the targeted IL-4R alpha, the expression sequence of the first nucleic acid molecule and the immune compatible molecule, the genes related to shRNA and/or miRNA processing complex, the anti-interferon effector molecule, the inducible gene expression system and the exosome processing synthetic gene adopts a method of viral vector interference, non-viral vector transfection or gene editing.
20. The pluripotent stem cell or derivative thereof of claim 18, wherein: the introduction sites of the expression sequence of the shRNA and/or shRNA-miR of the targeted IL-4R alpha, the expression sequence of the first nucleic acid molecule and the immune compatible molecule, the genes related to shRNA and/or miRNA processing complex, the anti-interferon effector molecule, the inducible gene expression system and the exosome processing synthetic gene are genome safety sites of the pluripotent stem cell or the derivative thereof;
preferably, the genome safe site comprises one or more of AAVS1 safe site, eGSH safe site, H11 safe site.
21. The pluripotent stem cell or the derivative thereof according to any one of claims 1 to 20, wherein:
the pluripotent stem cells comprise embryonic stem cells, embryonic germ cells, embryonic cancer cells, or induced pluripotent stem cells;
the pluripotent stem cell derivative comprises an adult stem cell, each germ layer cell or a tissue or organ into which the pluripotent stem cell is differentiated;
the adult stem cells include mesenchymal stem cells or neural stem cells.
22. An exosome secreted from the pluripotent stem cell according to any one of claims 1 to 21 or a derivative thereof.
23. Use of a pluripotent stem cell or derivative thereof according to any of claims 1 to 21 and/or an exosome according to claim 22 in an anti-allergic, atopic dermatitis and/or anti-asthma therapeutic.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011526223.3A CN114657133A (en) | 2020-12-22 | 2020-12-22 | Pluripotent stem cell for expressing shRNA and/or shRNA-miR of targeted IL-4R alpha |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011526223.3A CN114657133A (en) | 2020-12-22 | 2020-12-22 | Pluripotent stem cell for expressing shRNA and/or shRNA-miR of targeted IL-4R alpha |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114657133A true CN114657133A (en) | 2022-06-24 |
Family
ID=82025443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011526223.3A Pending CN114657133A (en) | 2020-12-22 | 2020-12-22 | Pluripotent stem cell for expressing shRNA and/or shRNA-miR of targeted IL-4R alpha |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114657133A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114457024A (en) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | Pluripotent stem cell expressing IL-4R alpha blocker or derivative thereof and application |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108368520A (en) * | 2015-11-04 | 2018-08-03 | 菲特治疗公司 | The genome project of pluripotent cell is transformed |
CN108779463A (en) * | 2016-02-02 | 2018-11-09 | 奥利克斯医药有限公司 | Use the RNA complex therapies atopic dermatitis and asthma of targeting IL4R α, TRPA1 or F2RL1 |
CN111542594A (en) * | 2017-12-22 | 2020-08-14 | 菲特治疗公司 | Enhanced immune effector cells and uses thereof |
CN111954715A (en) * | 2018-03-29 | 2020-11-17 | 菲特治疗公司 | Engineered immune effector cells and uses thereof |
-
2020
- 2020-12-22 CN CN202011526223.3A patent/CN114657133A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108368520A (en) * | 2015-11-04 | 2018-08-03 | 菲特治疗公司 | The genome project of pluripotent cell is transformed |
CN108779463A (en) * | 2016-02-02 | 2018-11-09 | 奥利克斯医药有限公司 | Use the RNA complex therapies atopic dermatitis and asthma of targeting IL4R α, TRPA1 or F2RL1 |
CN111542594A (en) * | 2017-12-22 | 2020-08-14 | 菲特治疗公司 | Enhanced immune effector cells and uses thereof |
CN111954715A (en) * | 2018-03-29 | 2020-11-17 | 菲特治疗公司 | Engineered immune effector cells and uses thereof |
Non-Patent Citations (2)
Title |
---|
FRANK R T等: "Concise review: stem cells as an emerging platform for antibody therapy of cancer", STEM CELLS, vol. 28, no. 11, 30 November 2010 (2010-11-30), XP055425379, DOI: 10.1002/stem.513 * |
汲晓沛等: "负性协同刺激分子B7-H4在C3H10T1/2移植治疗EAE中作用机制的研究", 第十届全国免疫学学术大会分会场交流报告(一), 14 November 2015 (2015-11-14) * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114457024A (en) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | Pluripotent stem cell expressing IL-4R alpha blocker or derivative thereof and application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022037481A1 (en) | Immunologically compatible and reversible universal pluripotent stem cell and application thereof | |
TW201321507A (en) | An inducible gene expression composition for using eukaryotic pol-2 promoter-driven transcription in prokaryotes and the applications thereof | |
CN107523569A (en) | The purposes and its related drugs of PDCD1 genes | |
CN114657133A (en) | Pluripotent stem cell for expressing shRNA and/or shRNA-miR of targeted IL-4R alpha | |
CN114645021A (en) | Pluripotent stem cell expressing targeted CD47 inhibitory factor, derivative and application thereof | |
CN114426953A (en) | Pluripotent stem cell derivative for expressing IL-12 and application thereof | |
WO2022116591A1 (en) | Pluripotent stem cell and derivative thereof | |
CN114657134A (en) | Pluripotent stem cell expressing IgE-targeted shRNA and/or shRNA-miR or derivative thereof | |
CN114657136A (en) | Pluripotent stem cell expressing shRNA and/or shRNA-miR of target PCSK9 or derivative thereof | |
CN114717193A (en) | Pluripotent stem cell expressing shRNA and/or shRNA-miR targeting B7-H5 or derivative thereof | |
CN114657137A (en) | Pluripotent stem cell or derivative thereof for expressing BTLA-targeted shRNA and/or shRNA-miR | |
CN114525255A (en) | Pluripotent stem cell derivative for expressing IL-11 and application thereof | |
CN114657138A (en) | Pluripotent stem cell expressing shRNA and/or shRNA-miR targeting B7-H4 or derivative thereof | |
CN114645020A (en) | Pluripotent stem cell expressing targeted NR4A1 inhibitory factor, and derivative and application thereof | |
CN114657139A (en) | Pluripotent stem cell expressing LAG-3 targeted inhibitory factor, derivative and application thereof | |
CN114657131A (en) | Pluripotent stem cell expressing urate oxidase or derivative thereof | |
CN114517184A (en) | Pluripotent stem cell expressing adipsin or derivative thereof and application thereof | |
CN114657132A (en) | Pluripotent stem cell expressing Siglec-15 targeted inhibitory factor, derivative and application thereof | |
CN114645018A (en) | Pluripotent stem cell expressing CD38 targeted inhibitory factor, derivative and application thereof | |
CN114525254A (en) | FGF-21-expressing pluripotent stem cell or derivative thereof and application | |
CN114657135A (en) | Pluripotent stem cell expressing Tim-3 targeted inhibitory factor, derivative and application thereof | |
CN114717192A (en) | Pluripotent stem cell expressing Amyloid beta targeted inhibitory factor, derivative and application thereof | |
CN114457035A (en) | Pluripotent stem cell expressing LAG-3 blocking substance or derivative thereof and application | |
CN114717232A (en) | Pluripotent stem cell expressing IRF-1 targeted inhibitory factor, derivative and application thereof | |
CN114350612A (en) | Pluripotent stem cell expressing CTLA-4-targeted shRNA/shRNA-miR or derivative thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |